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This study had four main aims. First, it aimed to explore the effects of nandrolone 
decanoate on dopaminergic and serotonergic activities in rat brains. Second, 
it set out to assess whether nandrolone pre-exposure modulates the acute 
neurochemical and behavioral effects of psychostimulant drugs in experimental 
animals. A third aim was to investigate if AAS-pretreatment-induced changes 
in brain reward circuitry are reversible. Finally, the study was also intended to 
evaluate the role of androgen receptors in nandrolone’s ability to modulate the 
dopaminergic and serotonergic effects of stimulants.
The results of the study show that AAS pretreatment inhibits the reward-
related neurochemical and behavioral effects of amphetamine, MDMA and 
cocaine in experimental animals. Given that LMA, stereotyped behavior and 
accumbal outflow of DA and 5-HT are all related to reward, this study suggests 
that nandrolone, at tested doses, significantly affects the rewarding properties 
of stimulant drugs. Furthermore, it seems that these effects could be long-
lasting and that the ability of nandrolone to modulate reward-related effects of 
stimulants depends on AR or ER activation.
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Abstract
Sanna Kailanto, Interactions of nandrolone and psychostimulant drugs on central 
monoaminergic systems. National Institute for Health and Welfare (THL), Research 
30. pp. 121. Helsinki, Finland 2010. 
ISBN 978-952-245-258-0 (printed), ISBN 978-952-245-259-7 (pdf)
It has been hypothesized that abuse of supra-therapeutic doses of anabolic 
androgenic steroids (AASs) can lead to dependence and function as a gateway to 
abuse of other drugs. This is supported by behavioral studies on animal models 
and psychiatric evaluations of human subjects, although their neurochemical 
effects remain largely unknown. A large body of evidence suggests that the ability 
of the drugs to induce a strong elevation of extracellular dopamine (DA) levels in 
the nucleus accumbens (NAc), especially, plays a crucial role in their reinforcing 
effects.
This study had four main aims. The first was to explore the effects of nandrolone 
decanoate on dopaminergic and serotonergic activities in the brains of rats, at 
doses which trigger the peripheral anabolic effects. The second aim was to assess 
whether or not nandrolone pre-exposure modulates the acute neurochemical and 
behavioral effects of psychostimulant drugs (amphetamine, MDMA and cocaine) 
in experimental animals. The third was to investigate if the AAS-pre-treatment 
induced changes in brain reward circuitry are reversible. And the fourth main goal 
was to evaluate the role of androgen and estrogen receptors in the modulation of 
the dopaminergic and serotonergic effects of acute injections of stimulant drugs 
by sub-chronic nandrolone treatment. The extracellular concentrations of the 
monoamine transmitters were monitored using in vivo microdialysis technique. 
The results showed that nandrolone decanoate at doses, high enough to 
induce erythropoiesis, significantly increased the levels of DOPAC and 5-HT 
in the cerebral cortex. Co-administration of AAS and psychostimulant drugs 
showed that the increase in extracellular DA and 5-HT concentration evoked by 
amphetamine, MDMA and cocaine in the NAc was attenuated dose-dependently 
by pretreatment with nandrolone. Nandrolone pre-exposure also attenuated the 
ability of stimulants to cause increased stereotyped behavior and locomotor activity. 
The results demonstrated also that despite the significant decrease in nandrolone 
concentration in blood, the attenuation of cocaine’s effects remained unchanged 
after a fairly long period without nandrolone, suggesting that nandrolone effects 
could be long lasting. Blockade of androgen receptors (ARs) with flutamide 
abolished the attenuating effect of nandrolone pretreatment on amphetamine-
induced elevation of extracellular DA concentration, while blockade of estrogen 
receptors (ERs) with clomiphene reduced the attenuating effect of nandrolone to 
a lesser extent.
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In conclusion, the results of this study show that AAS-pretreatment is able to 
inhibit the reward-related neurochemical and behavioral effects of amphetamine, 
MDMA and cocaine in experimental animals. Given that accumbal outflow of DA 
and 5-HT, as well as LMA and stereotyped behavior are all related to reward, this 
study suggests that nandrolone, at the doses tested, has a significant effect on the 
rewarding properties of stimulant drugs. Furthermore, it seems that these effects 
could be long lasting and it appears that the ability of nandrolone to modulate 
reward-related effects of stimulants is dependent on activation of AR or ER.
Keywords: amphetamine, anabolic androgenic steroid, cocaine, dopamine, 
MDMA, nandrolone, nucleus accumbens, 5-HT
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Abstract in Finnish
Sanna Kailanto, Interactions of nandrolone and psychostimulant drugs on central 
monoaminergic systems [Nandrolonin ja piristävien huumausaineiden yhteiskäy-
tön vaikutukset keskushermoston monoamiinijärjestelmään]. Terveyden ja hyvin-
voinnin laitos (THL), Tutkimus 30. 121 sivua. Helsinki 2010. 
ISBN 978-952-245-258-0 (painettu), ISBN 978-952-245-259-7 (pdf)
Anabolis-androgeenisten steroidien (AAS) väärinkäytön on todettu voivan joh-
taa riippuvuuteen kyseisistä aineista ja mahdollisesti edistävän myös muiden päih-
teiden käyttöä. Vaikka koe-eläimillä tehdyt käyttäytymistutkimukset samoin kuin 
ihmisten psykiatriset arvioinnit tukevat tätä näkemystä, taustalla olevista hermo-
kemiallisista tapahtumista ei kuitenkaan ole kattavaa tietoa. Nykyisten tutkimustu-
losten perusteella voidaan olettaa, että olennaista päihteiden palkitsevuudessa on 
niiden kyky nostaa solunulkoisen dopamiinin pitoisuutta, erityisesti accumbens-
tumakkeessa. 
Tämän tutkimuksen tarkoituksena oli tutkia nandroloni dekanoaatin vaiku-
tuksia rotan aivojen dopaminergiseen ja serotonergiseen hermojärjestelmään nan-
drolonin annoksilla, jotka aiheuttavat yleisesti tavoiteltuja perifeerisiä muutoksia, 
kuten punasolujen lisääntynyttä synteesiä. Lisäksi tutkittiin, muuttaako nandrolo-
nin annostelu amfetamiinin, MDMA:n eli ekstaasin ja kokaiinin välittömiä her-
mokemiallisia ja käytöksellisiä vaikutuksia koe-eläimissä. Tutkimuksessa selvitet-
tiin myös, välittyvätkö nandrolonin dopaminergisiä ja serotonergisiä vaikutuksia 
muuttavat ominaisuudet androgeeni- tai estrogeenireseptorien kautta. Välittäjäai-
neiden solunulkoiset pitoisuudet mitattiin in vivo mikrodialyysimenetelmällä. 
Tulokset osoittavat, että nandroloni lisäsi merkittävästi DOPAC:n ja 5-HT:n 
(serotoniinin) pitoisuutta rotan aivokuorella, annoksina, joiden havaittiin edis-
tävän myös punasolujen synteesiä. Nandrolonin ja piristävien huumausaineiden 
samanaikainen annostelu osoitti, että amfetamiinin, MDMA:n sekä kokaiinin 
ai heuttama dopamiinin vapautuminen accumbens-tumakkeesta väheni merkittä-
västi nandrolonin esiannostelun seurauksena. Dopamiinin vapautuminen oli riip-
puvaista nandrolonin annoksesta. Nandrolonin esiannostelun havaittiin vähentä-
vän myös näiden stimuloivien huumausaineiden kykyä lisätä eläinten kaavamaista 
käytöstä, kuten myös liikeaktiivisuutta.  Tulokset osoittavat lisäksi, että nandrolo-
nin ehkäisevä vaikutus kokaiinin vaikutuksille saattaa olla pidempikestoista. Vaik-
ka nandrolonin pitoisuuksien havaittiin laskeneen tai jopa hävinneen rotan veres-
tä, kokaiinin vaikutukset olivat edelleen lievempiä. Androgeenireseptorien salpaus 
flutamidilla palautti amfetamiinin kyvyn nostaa solun ulkoista dopamiinipitoi-
suutta accumbens-tumakkeessa nandrolonin esiannostelusta huolimatta. Estro-
geenireseptorien salpaus klomifeenillä palautti osittain kokaiinin kyvyn nostaa 
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solun ulkoista dopamiinipitoisuutta accumbens-tumakkeessa nandrolonin esian-
nostelusta huolimatta.
Yhteenvetona voidaan todeta, että anabolis-androgeenisen yhdisteen, nan-
drolonin, havaittiin ehkäisevän amfetamiinin, MDMA:n sekä kokaiinin palkitse-
via vaikutuksia, kun mitattiin accumbens-tumakkeen solun ulkoisen dopamiinin 
pitoisuuden sekä käyttäytymisen muutoksia koe-eläimillä.  Ottaen huomioon, että 
dopamiinin ja serotoniinin vapautuminen accumbens-tumakkeessa, kuten myös 
liikeaktiivisuuden sekä kaavamaisen käytöksen lisääntyminen, liitetään voimak-
kaasti huumausaineiden palkitsevuuteen, tulosten perusteella voidaan esittää, et-
tä nandroloni tässä testattuina annoksina vähentää piristävien huumausaineiden 
palkitsevuutta. Lisäksi näyttää siltä, että nämä muutokset saattavat olla pidempiai-
kaisia ja että nandrolonin vaikutukset välittyvät voimakkaasti juuri androgeeni- ja 
osittain estrogeenireseptorien välityksellä.
Avainsanat: accumbens-tumake, amfetamiini, anabolinen steroidi, dopamiini, eks-
taasi, kokaiini, nandroloni, serotoniini
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AADC  Aromatic amino acid decarboxylase
AAS  Anabolic androgenic steroid
ALAT  Alanine aminotransferase
ANOVA Analysis of variance
ASAT  Aspartate aminotransferase
AR  Androgen receptor
AUC  Area under the curve
CNS  Central nervous system
COMT  Catechol-O-methyltransferase
CPP  Conditioned place preference
DA  Dopamine
DAT  Dopamine transporter
DOPAC  3,4-dihydroxyphenylacetic acid
EDTA  Ethylenediamine tetraacetic acid
ER  Estrogen receptor
GABA  γ-Aminobutyric acid
GC/MS  Gas chromatograph/mass spectrometer
HPLC  High-performance liquid chromatography
HVA  Homovanillic acid
i.c.v.  Intracerebroventricularly
i.g.  Intragastric
i.m.  Intramuscular
i.p.  Intraperitoneal
i.v.  Intravenously
MAO  Monoamine oxidase
MDMA  3,4-methylenedioxymethamphetamine
NAc  Nucleus accumbens
s.c.  Subcutaneous
SEM  Standard error of the mean
SERT  Serotonin transporter
TH  Tyrosine hydroxylase
TPH   Tryptophan hydroxylase 
VMAT  Vesicular monoamine transporter
VTA  Ventral tegmental area
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1	 Introduction
A large number of young adults abuse anabolic androgenic steroids (AASs). This 
type of use probably involves more than a desire to enhance the users’ appearance 
or sports performance, and appears to have much in common with the use of 
alcohol and tobacco (Bahrke et al., 2000; Kindlundh et al., 1999). AASs have been 
proposed to be addictive in humans and to serve as a gateway to abuse of other illicit 
drugs (Arvary and Pope, 2000; Kanayama et al., 2003; Skarberg et al., 2008). Loss of 
impulse control, often reported among AAS abusers, not only underlies aggression, 
but could also contribute to the initiation of drug abuse as well as its development 
into drug addiction (Kreek et al., 2005; Wood, 2004). Since the use of both 
psychostimulant drugs and anabolic steroids has increased over the past 20 years 
among young people, the question is raised what happens if these drugs are used 
simultaneously. Indeed, frequency of AAS use is significantly associated with the 
frequency of using psychotropic drugs such as cocaine and amphetamine (Thevis 
et al., 2008). While the side effects of both anabolic steroids and psychostimulant 
drugs have been well documented, very few studies have been performed to assess 
the potential effects resulting from the concomitant use of these drugs. It has been 
hypothesized that steroid hormones are important determinants of stimulant’s 
effects on behavior by influencing neuronal activity and plasticity (Hruska and 
Pitman, 1982; Perrotti et al., 2000; Quinones-Jenab et al., 2001).
The question whether AASs create dependence or not is without a 
definite answer. Several studies have shown that chronic AAS use may cause 
dependence (Brower et al., 1989; Brower et al., 1991; Clark et al., 1996), but the 
underlying biochemical mechanisms of AASs are still poorly understood. The 
mesocorticolimbic dopaminergic pathway is considered to play an important role 
in the reward circuitry of the brain (Di Chiara, 1995; Koob, 1992; Tomkins and 
Sellers, 2001), and a connection between AASs and central dopaminergic activity 
has been reported in animal studies (Kindlundh et al., 2001b; Thiblin et al., 1999; 
Vermes et al., 1979). Moreover, it is suggested that the serotonergic system is 
involved in the rewarding effects of various drugs (see review Leshner and Koob, 
1999). 
Given that AASs modulate functions of the brain reward systems, it is 
likely that in addition to a desire to enhance one’s exterior features or sporting 
performance there are also neurochemical adaptations behind prolonged misuse of 
AASs. Despite increased awareness of both the public and scientific communities 
of the profound neural changes AASs are able to induce, experimental research on 
their neurobiological basis is limited.
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2	 Review	of	the	literature
2.1  Anabolic androgenic steroids (AASs)
In 1889, C.E. Brown-Séquard injected on himself an extract isolated from dog and 
guinea pig testicles, and described it as a “rejuvenating elixir” much before the 
recognition of testosterone (Brown-Séquard, 1889). A small volume of testosterone 
itself was isolated from enormous amount of bovine testicles in 1927. Testosterone 
was later reported to restore masculine characteristics in several species after 
castration (Koch, 1938). 
Anabolic androgenic steroids (AASs) are defined as synthetic derivatives of 
the endogenous sex hormone testosterone. The largest amounts of testosterone 
are produced in the testes in men. In women it is also synthesized in far smaller 
quantities in the ovaries, as well as in the adrenal cortex in both sexes. In general, 
androgens promote protein synthesis and growth of those tissues with androgen 
receptors. Testosterone is responsible for the anabolic effects including growth of 
muscle mass and strength and androgenic effects including maturation of male 
secondary sex characteristics. The effects of testosterone in humans and other 
vertebrates occur by two main mechanisms: by activation of the androgen receptors 
(ARs), and by conversion to estradiol and activation of certain estrogen receptors 
(ERs). The brain is one of the important tissues in humans where the primary effect 
of testosterone is mediated via aromatization to estradiol. 
Testosterone was synthesized by two groups independently, and this earned 
the group leaders Butenandt and Ruzicka the joint Nobel Prize in Chemistry in 
1939 (Hoberman and Yesalis, 1995). The development of synthetic steroids started 
from this point. Testosterone and its synthetic derivates have been used clinically 
to treat e.g. hypogonadism, anemia and protein deficiency as well as severe weight 
loss associated with chronic diseases (Basaria et al., 2001; Shahidi, 2001). The 
anabolic effects of AASs made these substances attractive also outside clinical use. 
The first reports of athletes using AASs appeared in the literature during the 1950s 
(Hoberman and Yesalis, 1995), and even though sports organizations have banned 
these substances and perform tests regularly, doping scandals in sport are still a 
common experience.
Known modifications of testosterone molecule include alkylation at the 
17α-position and/or modification of the steroid ring structure. The goal of these 
modifications is the production of derivates that are more anabolic and less 
androgenic than the parent molecule. The esterification of the 17β-hydroxyl group 
also increases the steroid activity due to the prolongation of the action, as the steroid 
gets lipophilic properties and the capability of retaining in fat tissue (Fragkaki et al., 
2009). Table 1 summary the different kind of AASs.
2   Review of the literature
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TABLE 1. Commonly abused anabolic-androgenic steroids. 
Orally used 17α-alkylated 
testosterone derivatives
Intramuscularly used 
17β-esterificated testosterone derivatives
methandienone
methyltestosterone
oxandrolone
oxymetolone
stanozol
ethylestrenol
fluoxymesterone
danatsol
mesterolone
metenolone
trenbolone
Testosterone esters:
cypionate
propionate
enantate
undecanoate
Nandrolone esters:
decanoate
phenylpropionate
undecanoate
laurate
Other:
methenolone
trenbolone
boldenone
stanotzol
drostanolone
2.1.1  Nandrolone Decanoate 
TABLE 2. Nandrolone decanoate.
Nandrolone decanoate (19-nortestosterone decanoate)
Mol wt    
428.65
Solubility
insol in water, freely sol in ethanol, ether, acetone, chloroform, oils.
Half-life 
4.3 h
Half-life for the release of the ester from the i.m. depot
Rat: 4.3–5.4 days / Human 6–8 days
Metabolites:
19-norandrosterone, 19-noretiocolanolone, 19-norepiandrosterone
Receptors:
Androgen, Estrogen, Glucocorticoid, Mineralocorticoid.
2   Review of the literature
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FIGURE 1. Structural formula of testosterone, nandrolone and nandrolone decanoate. Nandrolone decanoate 
is hydrolysed by esterases to nandrolone after systemic administration. 
 
This thesis is focused on nandrolone; one of the most commonly abused AAS 
(Brower, 2002; Eklof et al., 2003). Nandrolone is a synthetic modification of the 
testosterone molecule and lacks a methyl (CH3) group at the C19 position (Fig. 
1). The nandrolone molecule is made suitable for injection by conjugation with 
decanoic acid, creating nandrolone decanoate (Fig.1). Nandrolone has a long half-
life in the depot form, but after injection nandrolone decanoate is converted to 
nandrolone when it is slowly released from the depot into the blood. 
 
2.1.2  Mechanism of action
Anabolic steroids pass through the cell membrane and bind to the cytoplasmic 
androgen receptor (AR). The androgen receptor is a member of the nuclear 
receptor superfamily. When the receptor is occupied by a ligand, it is classically 
translocated to the cell nucleus where it functions as a transcription factor and 
modulates gene expression, which in turn results in many physical changes. Each 
AAS has a different binding affinity for the AR, and it is believed that this varying 
receptor affinity explains the varying effects produced by different AASs (Pereira 
de Jesus-Tran et al., 2006). Nandrolone, the AAS examined in this thesis, binds the 
AR with less affinity than the testosterone metabolite, dihydrotestosterone but with 
a higher affinity than testosterone (Roselli, 1998; Thompson and Siiteri, 1974). 
More recent studies in rats have also demonstrated “non-classical” rapid 
cellular effects of androgens in brain regions that possess few classical receptors 
(Mermelstein et al., 1996). These steroid actions are thought to be mediated 
membrane steroid receptors (Sato et al., 2008). Whereas the distribution of classical 
steroid receptors in the rodent brain is relatively limited, the potential brain targets 
for membrane androgen action are much broader. The simultaneous modification 
2   Review of the literature
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of both “classical” and “non-classical” target sites may account for the complex 
AAS abuse syndrome. 
The CNS actions of AASs are complex and the response depends not only 
on their interaction with ARs in the brain, but also on their ability to regulate 
and/or act as substrate for aromatase. Aromatase is an enzyme that is responsible 
for a key step in the biosynthesis of estrogens (Fig 2). Aromatase transforms 
androgens to estrogens through oxidation and subsequent elimination of 
a methyl group (Schade and Schubert, 1979). Increased circulating levels of 
estrogen are shown to be present after the administration of AASs (Lukas, 1993) 
and the estrogenic activity of nandrolone has been established (Ryan, 1959). 
FIGURE 2. Aromatase converts testosterone to estradiol. 
2.1.3  Abuse of AAS
Apart from elite athletes aiming for increased performance during competition, 
both professional and amateur bodybuilders administer AASs to gain maximal 
muscle volume. During the past decade their use has spread to colleges and high 
schools as well (Kochakian, 1990; Lukas, 1993). Over the last years, several studies 
examining substance use-patterns have shown an increase in anabolic-androgenic 
steroids (AASs) in all user groups, not only in athletes (Graham et al., 2008; 
Parkinson and Evans, 2006). The use of AASs is no longer limited to professional 
power training athletes and body builders, but a large number of young adolescents 
take AASs in high doses with the intention of improving their physical fitness, 
appearance, increasing of confidence levels, and even pleasure (Faigenbaum et 
al., 1998; Kindlundh et al., 2001a; Kindlundh et al., 1998; Kindlundh et al., 1999; 
Yesalis and Bahrke, 1995).
However, this misuse probably involves more than a desire to enhance the user’s 
appearance or sporting performance: it also appears to have much in common with 
the use of alcohol and tobacco (Bahrke et al., 2000; Kindlundh et al., 1999). According 
to recent surveys, people who abuse AASs also tend to abuse psychotropic drugs 
such as cocaine, heroin, amphetamine and 3,4-methylenedioxymethamphetamine 
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(MDMA or “ecstasy”); (DuRant et al., 1995; Kindlundh et al., 2001a; Thevis et al., 
2008). One explanation for the popularity of stimulant drugs among steroid users 
could be the fact that they increase fat burning and induce a sensation of an “energy 
burst” that makes the user train even harder (Brower, 2002). This trend is alarming 
because, while the side effects of both anabolic steroids and stimulants have been 
well documented, very few studies have been performed to assess the potential 
effects resulting from the concomitant use of these drugs. For example, it has been 
hypothesized that steroid hormones are important determinants of cocaine’s effects 
on behavior by influencing neuronal activity and plasticity (Hruska and Pitman, 
1982; Perrotti et al., 2000; Quinones-Jenab et al., 2001).   
2.1.4  Physical and mental side effects                                                                 
To reduce many of the mental side effects of AAS, it is desirable to promote the 
anabolic rather than the androgenic effects. However, pure anabolic steroids do 
not yet exist. Although most of the synthetic AASs exhibit less androgenic activity 
than testosterone, they induce a variety of physical side effects (e.g. Bahrke 
and Yesalis, 2004; Wollina et al., 2007). In brief, gynecomastia, baldness, testes 
and prostate atrophy have been reported in men, while deepening of the voice, 
menstrual irregularities, increased growth of facial hair and enlargement of clitoris 
are commonly reported side effects in women after prolonged AAS use (see review 
Bahrke and Yesalis, 2004). Increased acne, liver dysfunction, as well as increased 
risk of cardiovascular diseases (for example altered serum lipoproteins, stroke, 
enlarged heart) are found in both sexes (Karila et al., 2003; Sader et al., 2001).
The mental side effects associated with AASs have been observed more 
frequently as the use of AASs has become more widespread. Changes in mood, 
euphoria, delusions, depression and violent behavior, are reported to be associated 
with the prolonged use of AASs (Bahrke et al., 2000; Burnett and Kleiman, 1994; 
Choi and Pope, 1994; Copeland et al., 2000; Gruber and Pope, 2000; Parrott et al., 
1994; Parssinen et al., 2000; Perry et al., 2003). The neurochemical mechanisms 
behind AAS-induced mental side effects are not clear. Nevertheless, on the basis of 
animal studies, it has been suggested that AAS abuse may constitute a risk factor 
in aggressive behavior, partly by affecting the serotonergic system (Lindqvist et 
al., 2002; Miczek et al., 1994) and drug dependence by affecting the dopaminergic 
system in the brain (Kindlundh et al., 2001b; Thiblin et al., 1999; Vermes et al., 
1979). 
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2.1.5  AAS Dependence
No cases of abuse or dependence have been described in men or women who 
received or self-administered therapeutic doses of AASs for medical indications. 
However, when used for enhancing physical appearance, AASs can lead to abuse 
and dependence in both men and women (Brower et al., 1991; Brower et al., 1990; 
Kashkin and Kleber, 1989). Brower (2002) has proposed a two-stage model of 
AAS dependence. According to this hypothesis, anabolic effects on muscle growth 
account for the fist stage of steroid use. However, with chronic exposure, users 
can develop physical and psychological dependence on AASs, as defined by DSM-
III-R (Diagnostic and Statistical Manual of Mental Disorders, 1987). Regarding the 
background literature AASs abusers share personality factors with the abusers of 
psychotropic substances, such as cannabis, amphetamine and cocaine (Arvary and 
Pope, 2000; Kanayama et al., 2003; Lukas, 1996; Skarberg et al., 2008).
2.1.5.1  Animal models
While it is clear that AASs are abused, defining the potential for addiction in 
humans has been problematic because it is difficult to separate direct psychoactive 
effects the drugs in humans from the user’s psychological dependence on the 
anabolic effects of AASs. Thus, studies in laboratory animals are a useful tool 
to explore androgen reward. Several experimental models have been developed 
to study reward in laboratory animals (Koob, 2006), where conditioned place 
preference (CPP) and self-administration are the most important methodologies. 
Testosterone, like many drugs of abuse, will increase rates of bar pressing 
for electrical brain stimulation, which is considered an indication of a drug’s 
rewarding effects (Caggiula, 1970; Campbell, 1970; Olds, 1958). Male hamsters 
preferentially self-administer testosterone orally (Johnson and Wood, 2001; Wood, 
2002), and in many studies the testosterone induces conditioned place preference 
(Alexander et al., 1994; de Beun et al., 1992; Kashkin and Kleber, 1989). To the 
author’s knowledge, there is only one CPP-study carried out with nandrolone, and 
it shows that nandrolone is able to induce CPP in mice (Parrilla-Carrero et al., 
2009). Both Syrian hamsters and Sprague-Dawley rats self administer testosterone 
intravenously (i.v.) (Wood et al., 2004). Syrian hamsters have also been shown 
to self-admister nandrolone (Ballard and Wood, 2005). As seen, AASs are self-
administered by rodents, although the effect is known to be rather modest. Still, 
it is comparable with other mild reinforcers such as benzodiazepines (Naruse and 
Asami, 1987) and nicotine (Manzardo et al., 2002). 
Pre-exposure to AASs has been demonstrated to affect the response to other 
substances of abuse in experimental animals. Nandrolone decanoate is shown to 
block CPP induced by food, tetrahydrocannabinol and morphine (Celerier et al., 
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2006; Celerier et al., 2003). Male adult rats have been shown to increase voluntary 
alcohol intake after cessation of AAS-administration (Johansson et al., 2000b). 
2.1.5.2  Neurotransmitters
One way to investigate the abuse potential and risk of development of dependence 
after use of AASs is to study the steroid’s effect on neurotransmitters known to 
regulate the rewarding effects of other drugs of abuse as well. Animal studies 
have indicated that AASs are able to evoke biochemical changes in dopaminergic 
and serotonergic neuronal systems related to reward, a key phenomenon in 
drug dependence, as well as numerous other behavioral responses in rats (Bitar 
et al., 1991; Thiblin et al., 1999; Vermes et al., 1979). Testosterone-induced CPP 
can be blocked by the mixed dopamine D1/D2 receptor antagonist, flupenthixol, 
administered both systemically (Schroeder and Packard, 2000) or directly into 
the NAc (Packard et al., 1998) in doses which do not impair motor behavior. I.p. 
injections of the specific dopamine D1 antagonist SCH23390 or D2 antagonist 
sulpiride can also block testosterone induced CPP, indicating involvement of both 
dopamine D1 and D2 receptors (Schroeder and Packard, 2000). 
2.2  Neuropharmacology of brain reward   
 system
It is generally believed that most drugs of abuse, if not all, act through a so-called 
brain reward system, a general name for the mechanism involving the brain 
neurotransmitter DA and the neural system that it regulates. The mesocorticolimbic 
dopaminergic pathway plays an important role in the reward circuitry of the brain. 
A large body of literature is devoted also to the influence of serotonergic systems 
in mediating physiological responses and behaviours to addictive substances. 
The brain reward system is activated by natural stimuli essential for survival and 
reproduction, such as eating and sexual activity, but addictive drug activates this 
circuitry even more strongly than these natural stimulants (Di Chiara, 1999). 
2.2.1  DA
2.2.1.1  The dopaminergic system
The cell bodies of dopaminergic neurons projecting to the forebrain are located in 
the brain stem, more specifically in the substantia nigra (A9), ventral tegmental 
(A10; VTA) and retrorubral areas (A8). Mesolimbic and mesocorticolimbic 
2   Review of the literature
21Interactions of Nandrolone and Psychostimulant Drugs 
on Central Monoaminergic Systems
Research 30/2010
National Institute for Health and Welfare
dopaminergic pathways originate mainly in the VTA, from where they project 
to the nucleus accumbens, olfactory tubercle, medial caudate putamen, septum, 
amygdala, hippocampus, limbic cortex and other brain areas, fig 3 (Björklund, 
1984; Dahlström and Fuxe, 1964).
FIGURE 3. Schematic diagram illustrating the distribution of the main central neuronal 
pathways containing dopamine, modified by Cooper (2003). 
Catecholamine neurotransmitters are synthesized from the dietary amino acid 
L-tyrosine. The biosynthesis of DA is presented in figure 4 (next page). The first 
reaction, where tyrosine is converted to L-3,4,-dihydroxyphenylalanine (L-DOPA), 
is catalyzed by tyrosine hydroxylase (TH), and is the rate-limiting step (e.g. Cooper, 
2003). L-DOPA is subsequently converted to DA by the enzyme aromatic L-amino 
acid decarboxylase (AADC).
Newly synthesized DA is transported into synaptic vesicles by the vesicular 
monoamine transporter 2 (VMAT2), and stored in these vesicles awaiting release, 
which occurs after action potential or other depolarizing stimulus by exocytosis of 
a Ca2+ ion dependent manner into the synaptic cleft (Raiteri et al., 1979). 
DA released into the synaptic cleft binds to receptors that belong in two 
families: D1 and D2. D1-like receptors include D1 and D5 types, whereas D2-like 
receptors include D2, D3 and D4 types. The receptors can be differentiated on the 
basis of biochemical function, cellular location and distribution profile over the 
brain (Cooper, 2003; Waxham, 1999). All of these receptors are known to belong to a 
family of guanine-nucleotide binding protein (G-protein) coupled transmembrane 
receptors, but there are two sub-families that have opposite effects at cellular level: 
action of D1–like receptors results in stimulation of the enzyme adenylate cyclase, 
while activation of D2–like receptors inhibits adenylate cyclase. DA receptors can 
be located either post- or presynaptically. 
Synaptic action of catecholamines is primarily terminated by efficient Na+ and 
K+ dependent transporter-mediated uptake into nerve-endings (uptake 1). There 
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is, however, also some uptake into surrounding tissue (uptake 2). DA homeostasis 
is maintained through several mechanisms, one being uptake by the plasma 
membrane bound DA transporter (DAT) and other is synthesis of DA (Jaber et 
al., 1997). DA metabolism may follow either of two routes, which is determined 
by whether the first step is catalyzed by monoamine oxidase (MAO) or catechol-
O-methyltransferase (COMT). MAO and COMT are located in mitochondria of 
nerve endings and glia cells. MAO metabolizes cytosolic DA into DOPAC, which 
is the main metabolite in rats (Westerink, 1985). DA is metabolized by COMT and 
MAO into HVA, which is the major metabolite in humans (fig 4) (Cooper, 2003).
FIGURE 4. Simplified presentation of DA synthesis and metabolisms.
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2.2.1.2  Nandrolone decanoate and DA
The impact of AASs, particularly nandrolone, on the brain dopaminergic systems 
has been studied to some extent in rodents. Two-week dosing of nandrolone 
decanoate at 15 mg/kg daily decreased density of dopamine D1-like receptor 
protein in the caudate putamen and NAc core and shell (Kindlundh et al., 2001b). 
Similar results were later obtained for mRNA levels (Kindlundh et al., 2003b). On 
the other hand, the densities of dopamine D2-like receptors were upregulated in the 
caudate putamen, VTA and NAc core, while downregulated in the shell (Kindlundh 
et al., 2001b). Sub-chronic nandrolone administration to rats causes alterations in 
mRNA expression of DA receptors. An increase was detected in the D1 –receptor in 
amygdala and the D4 in the NAc, and a decrease in D1 receptor in the hippocampus 
(Birgner et al., 2008). In these studies, no changes in gene expression of TH or 
AADC were detected. 
The daily dosing of nandrolone at 1, 5 and 15 mg/kg for 14 days increased 
amounts of DAT in the caudate putamen (Kindlundh et al., 2004) and treatment 
with nandrolone (15 mg/kg/day for 14 days) caused an up-regulation of the 
binding potential of the DAT in the striatum (Kindlundh et al., 2002). This could 
explain some of the alterations seen in DA receptors after nandrolone dosing, since 
receptor number or activity could be affected by nandrolone’s actions on increased 
DA up-take by DAT. 
Nandrolone pre-treatment (15 mg/kg/day for 14 days) has been shown to 
attenuate amphetamine-induced decreases of the DA metabolite levels (Birgner 
et al., 2007). Furthermore, nandrolone decanoate pre-treatment is shown to 
abolish the effect of amphetamine on the hippocampal DOPAC/DA ratio and the 
hypothalamic DOPAC level and DOPAC/DA ratio (Birgner, 2006). This reduced 
metabolism might possibly be a compensation for increased DA uptake, since the 
DA baseline levels remains unchanged. This is in line with earlier findings of DAT 
up-regulation. Nandrolone has not been shown to change the MAO-A or MAO-B 
activity in rats (Thiblin et al., 1999).
2.2.2  5-HT
2.2.2.1  The serotonergic system
5-HT-containing neurons are restricted to clusters of cells lying in or near the 
midline or raphe regions of the pons and upper brain stem (Figure 5). Dahltröm 
and Fuxe described nine 5-HT containing cell groups (B1-B9), which exist in 
midbrain and brainstem areas of the raphe nuclei and the reticular area (Dahlström 
and Fuxe, 1964). The more caudal groups project largely to the medulla and spinal 
cord and the more rostral cell groups (B7-B9) are thought to provide the extensive 
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5-HT innervations of the telencephalon and diencephalon. The intermediate 
groups may project into both ascending and descending groups (Cooper, 2003). 
FIGURE 5. Schematic diagram illustrating the distribution of the main serotonin-containing 
pathways in the rat central nervous system, modified by Cooper (2003).
 
5-HT is derived from dietary amino acid tryptophan (figure 6). The first 
step in the synthetic pathway is hydroxylation of tryptophan at the 5 position 
by tryptophan hydroxylase (TPH) to form 5-hydroxytryptophan (Walther et al., 
2003). Once synthesized, 5-hydroxytryptophan is sequentially converted to 5-HT 
by AADC. Like DA, newly synthesized 5-HT is transported into synaptic vesicles 
by VMAT2 and stored in, and released from these vesicles (Cooper, 2003). 
5-HT released into the synaptic cleft binds to receptors that belong in seven 
families (5-HT1-7) and several of these are further subdivided (Barnes and Sharp, 
1999). In general, 5-HT1 -family receptors (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F) 
are negatively coupled to adenylate cyclase and are considered as autoreceptors. 
5-HT1 -family receptors can also exist as heteroreceptors localized on axon 
terminals of non-serotonergic neurons, postsynaptic to the 5-HT releasing neuron 
(Zifa and Fillion, 1992). The members of 5-HT2 –family receptors (5-HT2A, 5-HT2B, 
5-HT2C, 5-HT2D, 5-HT1F) are postsynaptic receptors and activate phospholipase 
C (Cooper, 2003). Other positively adenylyl cyclase coupled 5-HT receptors are 
5-HT4, 5-HT6 and 5-HT7 subtypes. The 5-HT5 group (5-HT5A, 5-HT5B) represent 
a new family of 5-HT receptors that do not resemble the 5-HT1 or 5-HT2 families 
and have a still unknown coupling mechanism, and which seem to be widespread 
within the CNS (Erlander et al., 1993). In contrast to G-protein coupled receptors, 
the 5-HT3 receptors directly activate a 5-HT –gated cation channel. 
Synaptic action of 5-HT is primary terminated by efficient Na+ and K+ 
dependent transporter-mediated uptake into nerve-endings. 5-HT homeostasis 
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is maintained through uptake by the plasma membrane bound 5-HT transporter 
(SERT) (Cooper, 2003). After uptake to a nerve-ending 5-HT is recycled or 
metabolized by monoamine oxidase (MAO) to 5-HIAA (figure 6). 
FIGURE 6. 5-HT synthesis and metabolism.
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2.2.2.2 Nandrolone decanoate and 5-HT
So far, there are only sparse reports on the ability of nandrolone to affect 5-HT 
and 5-HIAA synthesis or metabolism, and their reported measured tissue contents 
after nandrolone dosing are highly diverse. Tamaki et al. (2003) have observed 
increased levels of 5-HT and 5-HIAA in the cerebral cortex and hypothalamus 
after nandrolone treatment in the brains of rats, and Thiblin et al. (1999) has 
earlier documented similar results with oxymethenolone. With the 15 mg/kg 
does of nandrolone decanoate administered for 14 days to male rats, Lindqvist 
et al. observed decreased levels of 5-HT in the forebrain and dorsal striatum and 
decreased levels of 5-HIAA in the striatum (Lindqvist et al., 2002). The tryptophan 
hydroxylase activity of individual nuclei of the limbic system, hypothalamus, and 
midbrain was determined by Kritzer et al. after testosterone treatment, and no 
changes in activity occurred in any of the areas examined (Kritzer, 1997). To author’s 
knowledge, there are no studies carried out with nandrolone, but testosterone has 
been shown to increase the expression of SERT mRNA and the density of SERT 
sites in the forebrain (McQueen et al., 1999). 
Nandrolone has also been shown to induce alterations in the density of 5-HT 
receptors: 5-HT1B receptors were down-regulated and 5-HT2 receptors up-regulated 
in rat brain after two weeks of nandrolone dosing (Kindlundh et al., 2003a). With 
regard to 5-HT3 receptors, there are, to the authors knowledge, no studies carried 
out with nandrolone, but chronic administration of testosterone propionate was 
found to decrease the concentration of [3H]quipazine binding at 5-HT3 receptors 
(Mendelson and McEwen, 1990). Hamsters treated with anabolic/androgenic 
steroids (a mixture of AASs consisting of testosterone cypionate, nortestosterone, 
and dihydroxytestosterone) showed significant decreases in 5-HT1A receptor-
immunoreactive staining and protein levels in the anterior hypothalamus with 
no concomitant decrease in the number of 5-HT1A receptor-expressing neurons 
(Ricci et al., 2006). Testosterone is shown to increase SERT binding site densities 
in male rat brain (McQueen et al., 1999), and therefore these alterations seen in 
5-HT receptors after nandrolone dosing could be a result of nandrolone’s actions 
on increased DA up-take by SERT. 
2.2.3  Additional transmitters
In addition to dopamine and 5-HT, other systems like GABA and opioid –system 
contribute to modulation of brain reward mechanisms. 
Some behavioral evidence supporting for the regulatory role of the GABA-ergic 
system in psychomotor stimulant-reward have been obtained. Benzodiazepines, 
alprazolam and chlordiazepoxide, have been shown to attenuate cocaine self-
administration (Goeders et al., 1993; Goeders et al., 1989), and GABA transaminase 
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inhibitor has been shown to attenuate elevation in accumbal DA levels induced by 
cocaine (Morgan and Dewey, 1998). 
There is significant experimental evidence implicating that also the 
endogenous opioid system processes of reward and reinforcement. Indeed, 
many behaviors associated with reward and reinforcement, for example feeding 
behavior, are controlled by distinct components of the endogenous opioid system 
located in relevant brain regions (Gianoulakis, 2009). The main effect of opioid 
receptor stimulation seems to be inhibition of GABA-ergic interneurons, which 
in turn leads to disinhibition of the DA containing output neurons, activation of 
mesolimbic neural transmission and increased release of DA in the terminal area 
NAc (Di Chiara and North, 1992).
2.3  Psychostimulant drugs
The term “psychostimulant” generally refers to drugs that produce a spectrum of 
effects in humans which includes increased energy, cardiovascular stimulation, 
elevated mood, and a decreased need for sleep. At higher doses, or after longer 
periods of use, psychostimulant drugs can produce a range of disordered thought 
processes, including severe psychotic episodes (e.g. Le Moal and Koob, 2007). 
In animals, psychostimulants increase locomotor activity and are readily self-
administered due to their powerful reinforcing properties. Most psychostimulant 
drugs are known to interact with monoamine neurons in the CNS. One of the 
major brain areas involved in the rewarding properties of cocaine and particularly 
of amphetamine appears to be the NAc (Bardo, 1998; McBride et al., 1999).
In general, drugs that target transporter proteins, as psychostimulants do, can 
be divided into two classes based on their precise mechanism of action: reuptake 
inhibitors and substrate-type releasers (Rothman and Baumann, 2003). Reuptake 
inhibitors bind to transporter proteins, but are not themselves transported into the 
cells. They elevate extracellular transmitter concentrations by blocking transport-
mediated reuptake of transmitters from the synapse. Substrate-type releasers 
bind to transporter proteins, and these drugs are subsequently transported into 
the cytoplasm of nerve terminals. Releasers elevate transmitter concentration by 
promoting efflux of transmitters by a process of transporter-mediated exchange 
and disrupting storage of transmitters in vesicles (Rudnick and Clark, 1993). This 
latter action increases the pool of neurotransmitter available for release. 
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2.3.1  Amphetamine and MDMA
Amphetamine is a synthetic compound that was developed in the late 1880’s and it 
was medically used in the treatment of narcolepsy and a variety of other disorders 
from the 1936 to mid-1940s. Amphetamines were originally synthesized as 
potential alternative drugs for the treatment of asthma. Nowadays amphetamine is 
one of the standard treatments for ADHD, as well as narcolepsy and other sleeping 
disorders. After the 1930’s, when the CNS stimulating effect of amphetamine was 
discovered, it became a popular stimulant drug among university students in the 
United States. For military purposes amphetamine was first used in the Spanish 
Civil War, and at the end of the World War II there was a real epidemic of stimulant 
abuse (Angrist, 1978). Since the 1960s, amphetamine has been popular with many 
youth subcultures as a recreational drug. 
FIGURE 7. Molecular structure of amphetamine
3,4-Methylenedioxy-N-methylamphetamine (MDMA) was first synthesized 
in 1912, but was largely forgotten over the following 65 years (Bernschneider-
Reif et al., 2006). MDMA first appeared as a street drug in the early 1970s after 
its analogue, 3,4-methylenedioxyamphetamine (MDA), became criminalized in 
the United States. In the late 1980s MDMA marketed as “Ecstasy” began to be 
widely used, becoming an integral element of rave culture and other psychedelic 
and dance floor-influenced music scenes. Spreading along with rave culture, illicit 
MDMA use became increasingly widespread among young adults in universities 
and later in high schools. 
 
FIGURE 8. Molecular structure of MDMA
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In rats acute behavioral effects of amphetamine and MDMA include strong 
locomotor activation, and with higher doses of drugs, stereotyped behavior 
characterized by intense sniffing and head bobbing, which have shown to be of 
dopaminergic origin (Kulmala et al., 1987; Randrup and Munkvad, 1967; Taylor 
and Snyder, 1971). Both of these amines increase synaptic concentrations of 
DA by multiple mechanisms; by drifting into the nerve endings and displacing 
DA (and norepinephrine) from storage vesicles into the cytoplasmic pool 
from where it is released via reversal of the transporter, by inhibiting DA (and 
norepinephrine) reuptake, and by inhibiting MAO (Blaschko, 1952; Ferris et al., 
1972; Glowinski and Axelrod, 1965; Johnson et al., 1986). As measured using in 
vivo microdialysis, amphetamine elevates strongly and MDMA to a slightly lesser 
extent, the extracellular DA levels in the NAc and striatum (Hernandez et al., 1987; 
Hiramatsu et al., 1991; Nash, 1990; Zetterstrom et al., 1983), which are implicated 
in locomotor and stereotyped activity, respectively. Amphetamine and MDMA 
decrease extracellular concentrations of the DA metabolites DOPAC and HVA 
(Gough et al., 1991; Hernandez et al., 1987; Hiramatsu et al., 1991; Slikker et al., 
1988; Zetterstrom et al., 1983), since amphetamine is known to be a competitive 
and reversible inhibitor of MAO (Filinger and Stefano, 1982). Another reason 
could be that the majority of DOPAC is presumably derived from metabolism of 
intraneuronal DA and the cytoplasmic DA is partially depleted as a result of DA 
release (Kuczenski, 1980; Zetterstrom et al., 1986). HVA is a secondary metabolite 
of DOPAC, and thus changes in its concentrations should presumably parallel 
those of DOPAC. The effects of amphetamine (Kuczenski, 1980) and MDMA 
(Gough et al., 1991) on HVA indeed parallel the effects on DOPAC with small to 
moderate doses, but diverge at higher doses, which is suggested to result from DA 
metabolism shifting to an 3-methoxytyramine (3-MT) pathway. 
Extracellular 5-HT levels are elevated by higher doses of amphetamine, 
however with less efficiency than those of DA (Hernandez et al., 1987), whereas 
MDMA has been shown to affect 5-HT release and uptake more than those of 
DA (Johnson et al., 1986; Nichols et al., 1982; Schmidt et al., 1987). Elevation of 
extracellular 5-HT levels, induced by amphetamine and MDMA, is accompanied 
by a decrease in 5-HIAA levels. This can be assumed to result from depletion of 
cytoplasmic 5-HT, because 5-HIAA mirrors the metabolism of intraneuronal 
5-HT (Grahame-Smith, 1971). In addition, MDMA inhibits MAO-A (Leonardi 
and Azmitia, 1994), which may also result in decrease in extracellular 5-HIAA 
concentrations. Consistent with the neurochemical effects of MDMA, acute 
injection induces behavioral effects indicative of the so-called 5-HT syndrome, 
which in rats includes Straub tail and splaying of hind limbs (Slikker et al., 1989; 
Spanos and Yamamoto, 1989). The MDMA induced increase in locomotor activity 
is also 5-HT dependent (Callaway et al., 1991). Damage to 5-HT terminals following 
MDMA dosing is well documented, and results have shown that MDMA is more 
toxic to 5-HT terminals than some other stimulants (eg.. Baumann et al., 2007). It 
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seems that the 5-HT transporter may play a central role in MDMA toxicity, because 
it has been shown that exposure to methamphetamine which is structurally related 
to MDMA, only degenerates 5-HT transporter containing axons in the NAc, while 
the axons lacking the transporters are spared (Brown and Molliver, 2000). 
2.3.2  Cocaine
Cocaine (benzoylmethylecgonine) is a crystalline tropane alkaloid that is obtained 
from the leaves of the coca plant (Erythroxylon coca). For over a thousand years 
South American indigenous peoples have chewed the coca leaf. The history of 
cocaine use is thoroughly described in the literature (Gay et al., 1975). The cocaine 
alkaloid was first isolated by Albert Niemann in 1860. Chemically, cocaine is a 
benzoylecgonine methylester, which is an optically active crystalline base (figure 
9). In the 1880’s Sigmund Freud published a series of writings praising its effects, 
whilst his friend and colleague Karl Koller discovered its usefulness as a local 
anesthetic. The coca extract containing soft drink named Coca-Cola® appeared on 
the market in 1888, and it became one of the most popular soft drinks. In the 1890’s 
the disadvantages of cocaine use – development of dependence and toxic effects 
– were noticed, and in the year 1906 cocaine use became restricted in the United 
States. Since 1914 possession, selling and delivery of coca-products has been illegal, 
however cocaine is still the most widely abused psychostimulant drug of abuse 
today. 
 
FIGURE 9. Molecular structure of cocaine
 
In rats the acute behavioral effects of cocaine include those typical to 
psychostimulants: increased locomotor activity, and with higher doses of the 
drug stereotyped behavior, both of which have been shown to be dependent on 
the mesocorticolimbic dopaminergic network (Kelly and Iversen, 1976). Cocaine 
blocks the reuptake of DA, 5-HT and norepinephrine, thus increasing their synaptic 
concentration, without inducing transmitter release (Heikkila et al., 1975; Koe, 
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1976). As measured by in vivo microdialysis, cocaine strongly elevates extracellular 
levels of DA and 5-HT (and norepinephrine) at least in the NAc, striatum, prefrontal 
cortex and VTA, without any marked effect on neurotransmitter metabolites 
(Carboni et al., 1989; Hurd and Ungerstedt, 1989a; Hurd and Ungerstedt, 1989b; 
Kuczenski et al., 1991; Moghaddam and Bunney, 1989). Since the effect of cocaine 
on extracellular DA levels is prevented by treatment with γ-butyrolactone and 
tetrodotoxin, action potential is necessary for elevation of DA concentration 
(Carboni et al., 1989; Nomikos et al., 1990).
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3	 Aims	of	the	study
It has been hypothesized that abuse of supra-therapeutic doses of AASs can lead 
to dependence and function as a gateway to abuse of other illicit drugs. This is 
supported by behavioral studies in animal models as well as psychiatric evaluations 
of human subjects. A large body of evidence suggests that a drugs ability to induce 
a strong elevation of extracellular DA levels in the NAc, in particular, plays a 
crucial role in its reinforcing effects. Although AASs are abused by humans, their 
neurochemical effects remain largely unknown. Alterations of both DA and 5-HT 
functions are indicated as a possible neurochemical basis for these behavioral effects. 
However, the effects of supra-therapeutic doses of AASs on the dopaminergic 
and serotonergic systems are not yet fully evaluated. In order to understand the 
characteristics of addictive behavior and provide novel pharmacological treatment 
strategies for addiction diseases, it is essential to understand neurochemical 
mechanisms mediating the rewarding properties of drugs of abuse. 
The specific aims of this series of studies were:
1)  To evaluate the neurochemical effects of the AAS, nandrolone decanoate, on 
dopaminergic and serotonergic activities in the brains of rats, at doses that can 
cause physical effects.
2)  To assess whether or not nandrolone pre-exposure modulates the acute 
neurochemical effects of amphetamine, MDMA and cocaine, and behavioral 
effects of amphetamine and MDMA in rats.
3)  To investigate if the AAS-pre-treatment induced changes in brain reward 
circuitry, measured as altered response to stimulant drug of abuse, are 
reversible. 
4)  To examine, using androgen receptor antagonist and estrogen receptor 
antagonist, whether or not these hormonal systems are involved in 
nandrolone’s ability to modulate the dopaminergic and serotonergic effects of 
acute injection of amphetamine.
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4	 Material	and	methods
4.1  Animals
Studies were performed on adult male Wistar rats, weighing 290-380 g and they 
were delivered from Harlan Netherlands B.V., (Netherlands) at least 1 week prior to 
the experiments. In paper I the animals were housed individually in Macrolon III-
type cages (20 x 36,5 x 18,5 = 730 cm3) and in papers II, III and IV they were housed 
in groups of three in Techniplast Eurostandard type IV cage (595 x 380 x 200 mm, 
floor area 1820 cm²), except after surgery, when the rats were housed individually. 
The temperature- and humidity were controlled in the room (21 ± 2 ºC) with a 
12-h light cycle, during which time all the experiments were conducted. Standard 
laboratory chow (Altromin Nr. 1314; Chr. Petersen A/S, Ringsted, Denmark) and 
tap water were freely available. The animal experiments of papers I and II were 
approved by the local institutional committee for animal care and use and the 
chief veterinary surgeon of the county administrative board and those of papers 
III and IV were approved by the State Provincial Office of Southern Finland 
Animal Experiment Board. All studies were conducted according to the European 
Convention for the Protection of Vertebrate Animals used for Experimental and 
other Scientific Purposes.
4.2  Drugs and doses
4.2.1 Nandrolone
There are considerable differences, regarding experimental design, between 
existing neurochemical studies of supra-therapeutic AAS exposure in dose (1–
45 mg/kg), dose interval (1–7 days), duration of administration (1 day–15 weeks) 
and route of administration (i.m. or s.c). We chose the doses of 5 mg/kg and 20 mg/
kg nandrolone decanoate (Deca-Durabolin, N.V. Organon, the Netherlands) / 
body weight, calculated as free base, according to neurochemical and behavioral 
studies done with rats. We chose those doses also to correspond, at least in some 
level, to one cycle of use during early and experienced AAS abuse respectively, 
based on a one year follow-up study and a survey study of 500 AAS abusers (Fudala 
et al., 2003; Parkinson and Evans, 2006).
In papers I, II and III, both doses were used, and in paper IV was used only the 
larger nandrolone dose was used. In paper I the animals received one i.m. injection 
daily, 5 days per week during a two-week period (10 injections per animal). In rest 
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of the papers (II, III and IV) we injected nandrolone every other day during a 10-
day period (total of 5 injections per animal), based on our preliminary experiment 
which showed that combined the half-life (ester hydrolysis, distribution, and 
elimination) of nandrolone decanoate is 4.3 days, and on the study of van der 
Vies, who demonstrated that nandrolone depot has a half-life of 5.4 days in rat 
and 6 days in human (van der Vies, 1985). The injections were given in the left and 
right hind leg alternately. The matching vehicle for Deca-Durabolin, a mixture 
of arachinoid oil and benzylalcohol, was prepared by the University Pharmacy 
(Helsinki, Finland) for control purposes. 
4.2.2  Stimulant drugs
3,4-Methylenedioxymethamphetamine hydrochloride (National Institute on Drug 
Abuse; NIDA, Bethesda, MD USA) and amphetamine sulfate (Sigma Chemical co, 
St Louis, MO, USA) were dissolved in saline (0.9 % NaCl) at concentrations of 5 
mg/kg (MDMA) and 1 mg/kg (amphetamine), calculated as free base. Both drugs 
were racemic mixtures. The drugs were injected intraperitoneally (i.p.) in a volume 
of 1 ml/kg of body weight during the microdialysis experiment. The normal clinical 
oral dose of amphetamine is 0.07–0.2 mg/kg (Baselt, 2004), while addicts may 
self-administer doses as high as 0.7–4.3 mg/kg (Gustavsen et al., 2006). Typical 
amounts of MDMA abused by humans are one or two tablets of 80–100 mg orally, 
which corresponds to 1–3 mg/kg (Green et al., 2003). In addition to comparability 
to human doses, experiences from our earlier animal studies were taken into 
account: a 1 mg/kg dose of amphetamine and a 5 mg/kg dose of MDMA both 
produce robust and reproducible neurochemical and behavioral effects without 
any observable adverse effects on animal welfare. 
Cocaine hydrochloride (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
was dissolved in saline (0.9 % NaCl) at a concentration of 20 mg/kg (calculated as 
free base). The drug was a racemic mixture. The drug was injected i.p. at a volume 
of 1 ml/kg of body weight during the microdialysis experiment, on the 6th or 28th 
day from the last nandrolone injection. The cocaine dose chosen represents the 
minimum dose that produced strong stereotyped behaviours in rats and sufficient 
DA release from the NAc in without any observable adverse effects on animal 
welfare. 
4.2.3  Receptor antagonists
Flutamide (2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl] –propanamide; 
50 mg/kg (Sigma Chemical Co., St Louis, MO, USA), clomiphene (2-[4-(2-chloro-
1,2-diphenylethenyl)phenoxy] -N,N-diethyl-ethanamine; 20 mg/kg (Sigma 
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Chemical Co., St Louis, MO, USA) or water were administered intragastricly (i.g.) 
on days 1, 3, 5, 8 and 10 ca. 6 hours before nandrolone dosing, and continued also on 
days 12 and 15 from beginning of the experiment. Clomiphene was administered 
as a 10 mg/ml water solution and flutamide as 25 mg/ml water and Tween® 20 
suspension (Fluka Sigma-Aldrich Chemie GmbH, CH-9471 Buchs, Germany). 
 
4.3  Neuro- and biochemical experiments
4.3.1 Sample collection (paper I)
On day 1 and day 8 the rats were lightly anaesthetized with halothane gas (Trothane, 
I.S.C Chemicals Ltd., England) and a 0.5 ml blood sample was collected from the 
vena caudalis. The blood was collected in a tube containing 25 µl of Na2EDTA- 
UH-Q water solution (0.16 mM). Half of each sample was centrifuged at +4°C 
(1800 x g,) and the resulting plasma was stored at –20°C, while the other half 
was kept as whole blood at room temperature, from which the blood count was 
performed within 24 hours. The animals were rendered unconscious with CO2 
and decapitated on day 17 (3 days from the last injection) and trunk blood was 
collected and processed as described above. The brains were rapidly removed 
and the brain regions (olfactory bulb, prefrontal cortex, cerebral cortex, striatum, 
nucleus accumbens, hippocampus, hypothalamus, as well as pons and medulla) 
were dissected (Paxinos and Watson, 1986) and immediately frozen and stored at 
–70 °C until assayed. 
4.3.2  Surgery and microdialysis (papers II, III and IV)
The rats were anesthetized using halothane gas (Halothane Liquid BP; Rhodia 
Organique Fine Ltd., Bristol, UK) and mounted in a stereotactic frame on the 
first day after the last nandrolone dose (papers II and IV) For paper III half of the 
animals were taken into operation at the same stage as described above for papers 
II and IV, while the other half were taken into operation after a recovery period; 
on the 15th day after the last nandrolone dose. A guide cannula (CMA/12; CMA 
Microdialysis, Solna, Sweden) was implanted 2 mm above the NAc [A, +1.9; L, 
-1.0; D, -6.0 as calculated relative to the bregma and skull surface according to 
(Paxinos and Watson, 1986) and secured with two small screws and dental cement 
(Aqualox; VOCO, Cuxhaven, Germany). The animals received subcutaneously 
(s.c.) 0.05 ml of buprenorphium preparation (Temgesic, 0,3 mg/ml; Schering-
Plough Europe, Brussels, Belgium) to alleviate the pain, and were allowed to 
recover from the surgery for 5 days. 
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One day before the dialysis experiment, the rats were allowed to habituate 
to test cages and a microdialysis probe (CMA/12, membrane length 2 mm; CMA 
Microdialysis, Solna, Sweden) was inserted through the guide cannula into the 
NAc. On the day of the experiment, the animals were placed in test cages and 
probes were connected to a CMA/100 microinjection pump and perfused with 
modified Ringer’s solution (147 mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 
mM MgCl2, pH 6) at a flow rate of 2 µl/min. In order to prevent degradation of 
monoamine transmitters, a 6.5-µl aliquot of an aqueous antioxidant solution (1.0 
mM oxalic acid, 3.0 mM L-cysteine, 0.1 mM Acetic acid) was added to each vial 
before collecting the dialysate samples (Kankaanpää et al., 2001). The perfusate 
from the first 60 min was discarded, after which the samples were collected at 20 
min intervals. Amphetamine, MDMA, cocaine or saline was injected i.p. after 
collection of four basal samples. At the end of the experiment the animals were 
anesthetized with halothane gas, and blood samples were drawn using cardiac 
puncture (papers II and III). After decapitation, their brains were dissected out and 
immersed in buffered 10 % formalin solution to verify the correct placement of the 
probes. Only data from animals with accurate probe placements were included in 
statistical analyses.  
4.3.3  Chemical analyses
4.3.3.1  DA, 5-HT and their metabolites in brain tissue
The concentration of DA, 5-HT and their metabolites (DOPAC, HVA, and 5-HIAA) 
in brain tissues were determined using high performance liquid chromatography 
(HPLC) (ESA; ESA Inc., Chelmsford, MA USA) with electrochemical detection 
and an Insertil ODS-3V 5 µm (250 mm x 4.6 mm ID) reverse-phase column (GL-
Sciences Inc., Tokyo Japan) as described earlier (Kankaanpää et al., 2001), with 
necessary modifications for processing brain tissue samples. The frozen samples 
were homogenized in a 21-fold quantity of anti-oxidative solution (1.0 mM oxalic 
acid, 3.0 mM L-cysteine and 0.1 M acetic acid), using a Vibra-Cell VC 600 high 
intensity ultrasonic processor (Sonics and Materials Inc., Danbury, CT, USA) 
equipped with a tapered microtip. The processing time was 1.5 s and the amplitude 
was set at 40% of the maximum value. After a 10-minute centrifugation (5500 x 
g) at +4°C, the supernatants were filtered through a 0,45 µm Bulk Acrodisc LC 13 
mm filter (Pall Gelman Laboratory, USA). The sample volume to injector was 10 µl 
and the flow rate was 1.2 ml/min and potentials for detector electrodes were -175 
mV and +250 mV (cell 5014B).
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4.3.3.2  Selected blood parameters
The blood count was performed with an automated system composed of a Sysmex 
F-800 (Toa Medical Electronics Co., Japan) and a Sysmex Auto Diluter AD-260 (Toa 
Electronics, German). The following assays were carried: hemoglobin, red and white 
blood cells, hematocrit, MCV (mean corpuscular volume), MCH (mean corpus 
hemoglobin) and MCHC (mean corpus hemoglobin concentration). Reticulocytes 
were counted manually from a smear glass. Aspartate aminotransferase and alanine 
aminotransferase levels were determined from plasma samples according to the 
ECCL (European Committee for Clinical Laboratory) standards and creatinine 
(fS-Krea) by Jaffe´s reaction.
4.3.3.3  DA, 5-HT and their metabolites in dialysate samples
In order to determine DA, 5-HT and their metabolites DOPAC, HVA and 5-HIAA, 
20-µl aliquots of dialysate samples were injected into an ESA (ESA Inc. Chelmsford, 
MA, USA) high performance liquid chromatography (HPLC) apparatus equipped 
with an Inertsil ODS-3V 5 µm (4.6 X 250 mm ID) reverse-phase column (GL-
Sciences Inc., Tokyo, Japan) and a coulometric ESA Coulochem III detector. The 
mobile phase was a mixture of a buffer containing 50 mM NaH2PO4, 0.1 mM 
Na2EDTA, 2.3 mM octanesulfonic acid, and acetonitrile (14 % v/v in the final 
solution), with the pH adjusted to 3.0 with orthophosphoric acid (H3PO4). The 
mobile phase was filtered through a 47 mm Hydrophilic Polypropylene Membrane 
filter with a pore size of 0.22 µm (Gelman Sciences, Ann Arbor, MI, USA) and 
degassed under vacuum. The flow rate was 1.2 ml/min and the detector potentials 
of the two electrodes were –175 mV and +250 mV. 
4.3.3.4  Amphetamine, MDMA and cocaine in blood or brain tissue
Amphetamine and MDMA concentrations were analyzed with gas chromatography 
– mass spectrometry (GC-MS) by using a method described earlier (Kankaanpää 
et al., 2004). Briefly, amphetamine and MDMA were extracted from blood, and 
derivatized with heptafluorobutyric anhydride (HFBA) as follows: 200 µl of blood 
was mixed with 50 µl of alkaline buffer and 500 µl of extraction–derivatization 
reagent (toluene + HFBA + internal standard), centrifuged, and injected into a GC-
MS apparatus. When analyzing brain tissue samples, the procedure was as follows: 
The deep frozen rat brains were dissected sagittally along the fissura longitudinalis 
cerebri, the left hemispheres were weighed and homogenized in 4 ml of 0.1 M 
HClO4.  After centrifugation, 200-µl aliquots of the supernatants were transferred 
to clean test tubes and the extraction-derivatization was performed according to 
the procedure described for blood samples.  
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Trunk blood concentrations of cocaine and its metabolites benzoylecgonine 
and ecgonine methyl ester were measured using GC-MS. Briefly, cocaine and the 
metabolites were extracted from 1 ml of whole blood by solid phase extraction 
as follows: first, blood samples were acidified with sodium acetate buffer (pH 
4) containing the internal standard benzoylecgonine-d3 (IS). After shaking and 
centrifuging, the liquid phase was extracted with an IST Isolute HCX solid phase 
extraction column (International Sorbent Technology Ltd, Mid Glamorgan, UK) 
with a cation exchanger and C8 as an adsorbent. The eluates were evaporated 
to dryness and derivatized with pentofluoro-1-propanol (PFPOH) and 
pentafluoropropionic anhydride (PFPA) and incubated. The excess derivatization 
reagents were evaporated and the residues were re-suspended in ethyl acetate. 
Then, a 2-µl aliquot of the sample was injected into the GC-MS. The analysis was 
performed with an Agilent (Agilent Technologies, Palo Alto, CA, USA) 6890N gas 
chromatograph, an Agilent 5973 mass selective detector (EI, positive ions, 70 eV) 
and an Agilent ChemStation data system. The system was operated in the splitless 
injector mode. Helium was used as the carrier gas. The GC column was a DB-
35MS of length 30 m, internal diameter 0.32 mm and film thickness 0.25 µm (J&W 
Scientific Inc., Folsom, CA, USA). The column temperature was initially 120ºC 
with a hold time of 2 min, and was increased 15ºC/min, with a final hold time of 2 
min at 325ºC. The inlet and MSD transfer line heater temperatures were maintained 
at 250ºC and 300ºC, respectively. MS detection was performed in selected ion 
monitoring (SIM) mode. The limit of quantitation was 10 ng/ml for all the analyte. 
4.3.3.5  Nandrolone in blood samples
Blood nandrolone concentrations were measured with GC-MS as derivatives formed 
with N-methyl-n-(trimethylsilyl)trifluoroacetamide (MSTFA; Sigma Aldrich Co 
Ltd, Dorset, UK). The internal standard (IS), isotope labeled tetrahydrocannabinol 
(THC-D3) was from Cerilliant (Round Rock, TX, USA). Nandrolone was extracted 
from blood samples as follows: 5 ml of toluene containing IS was vortexed with 
0.5 ml of the sample. After centrifugation, the toluene layer was transferred into 
a clean test tube and evaporated to dryness. The dry residue was dissolved in 60 
µl of butyl acetate, and nandrolone (and IS) was derivatized with 15 µl of MSTFA. 
A 2-µl aliquot of the mixture was injected into an Agilent GC-MS (EI) apparatus 
equipped with a DB-35MS capillary column of length 30 m, internal diameter 320 
µm and film thickness 0.25 µm (J&W Scientific Inc., Folsom, CA, USA). The oven 
temperature was initially 150°C with a hold time of 1.0 min, and was increased 
15°C/min to 320°C, with a final hold time of 3.0 min. The lower limit of quantitation 
was set at 0.5 µg/l. 
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4.3.4  Timelines for dosing and experiments
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      & 
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Paper II & III 
Day1 
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Day 8 
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Paper I 
Day1 16 
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      & 
Decapitation 
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12 
Receptor antagonist dosing (7 times, every other day) 
Day 10 11 15 
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4.4  Behavioral experiments
4.4.1  Locomotor activity measurement
In papers II and III the behaviors of the rats during the microdialysis experiments 
were characterized from video tapes by an observer blind to drug conditions. 
Recording was begun 20 min before injection and continued for 160 min after 
the injection. Monitoring was discontinued for 20 min following the injection to 
exclude the effect of the injection. Locomotor activity of the animals was estimated 
from the number of complete passes across midline of the test cage at intervals of 
20 min (corresponding to the sampling interval in the microdialysis experiments). 
4.4.2  Characterization of drug-induced behavioral   
 changes
In addition, a more detailed behavioral analysis was performed at the same time 
intervals.  The beginning, frequency, and/or duration of different behavior was 
monitored visually for 1 min every 5th min. The behavioral patterns were scored 
according to a rating scale modified from previous studies described by Kankaanpää 
et al. (2002) and Chin et al. (2002). The rats were given a single behavioral score 
per each 1 min observation point and mean values were calculated for each 20-min 
sampling interval. Behavioral scores are seen in Table 3. 
TABLE 3. Description of the stereotype behavior and related scores (per 1 min observation 
point).
Scoring (points) Behavioral pattern
0:
1:
2:
3:
4:
5:
6:
7:
Passive motionlessness;
animal is stationary, lying or sleeping
Active motionlessness;
animal is lying, but alert
Active motionlessness with occasional movements
Sniffing, grooming, occasional locomotor activity
Locomotor activity with burst of rearings and slender agitation
Stereotyped behavior;
compulsive-like, rapid, and repetitive purposeless behavior, such as 
intensive sniffing (e.g. during a prolonged rearing), head or body 
weaving or head bobbing
Intense stereotyped behavior
Ataxia;
impairment in the ability of the animal to execute coordinated 
movements (Ataxia was defined as impairment in the ability of 
the animal to execute coordinated motor responses leading, in the 
extreme, to incapacitation*)
* According to Sturgeon et. al. (1979). 
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4.5 Statistical analysis
The body weights measured and blood samples collected from the animals before 
the treatments were considered to represent basal levels from which relative changes 
after treatments were calculated. The statistical comparisons of body weights and 
blood counts were performed with ANOVA for repeated measurements and pair 
wise comparisons were made using Bonferroni´s test. Neurotransmitter levels and 
plasma ASAT, ALAT and creatinine concentrations were analyzed by one-way 
ANOVA followed by Bonferroni´s test. In the microdialysis experiments the mean 
of the four samples before the drug treatments was considered as basal release (100 
%) of neurotransmitters, according to which relative changes after the injections 
were calculated. The absolute basal releases were calculated from the measured 
values. In the locomotor activity -test the absolute number of passes across the 
midline was counted, and for the more detailed behavioral analysis, scoring was 
conducted as described above. For statistical evaluations, both neurochemical 
and behavioral data were calculated as areas under the curves (AUC) with the 
trapezoidal method, after which the data was then subjected to one-way analysis 
of variance (ANOVA) followed by Tukey´s test. The results are presented as means 
± SEM (standard error of the mean) and the level of statistical significance was set 
at p ≤ 0.05. The behavioral scores were analyzed with the Mann-Whitney U test, 
or Kruskall-Wallis nonparametric ANOVA followed by the Mann-Whitney U test 
with Tukey´s adjustment for multiple comparisons. The results from measurements 
of MDMA blood concentrations were analyzed with one-way ANOVA followed 
by Tukey´s test. The correlation between neurochemical and behavioral data were 
analyzed with linear Pearson correlation method. The results are presented as 
means ± SEM (standard error of the mean) and the level of statistical significance 
was set at p ≤ 0.05. SPSS Statistics 16 was used as statistical program.
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5	 Results
5.1  The effects of nandrolone in brain regions  
 regulating motivation and reward-related  
 associative learning
5.1.1 Neurochemical measurements
The data from study I suggests that treatment with supra-therapeutical doses of the 
AAS nandrolone decanoate induces changes in the dopaminergic and serotonergic 
neuronal systems in the brains of rats. As evident from Table 4, both doses of 
nandrolone significantly increased the levels of DOPAC in the cerebral cortex, 
and 20 mg/kg of nandrolone increased the concentrations of 5-HT in the cerebral 
cortex. 
For the higher dose the 5-HT levels in the hypothalamus and in the 
hippocampus were higher when compared to the lower nandrolone dose, but not 
so much when compared to the control group. The 5-HIAA levels in the prefrontal 
cortex had increased in rats treated with nandrolone of 5 mg/kg compared with 
the control animals. Nandrolone (5mg/kg) significantly increased the DOPAC/DA 
ratio in the hypothalamus when compared with the control group. 
TABLE 4. Summary of the effects of two different nandrolone treatments on DA, DOPAC, 
HVA, 5-HT and 5-HIAA concentrations and ratios of DOPAC/DA, HVA/DA and 5-HIAA/5-HT 
in brains of rats. Only the results been found statistically significant (p < 0.05) in the original 
papers are presented here.
Control
Arach. oil
5 mg/kg
nandrolone
20 mg/kg
nandrolone
Cerebral cortex
     DOPAC
     5-HT
67 ± 5.6
163 ± 10.7
94 ± 8.3*
150 ± 8.9
113 ± 5.6**
203 ± 9.1*
Prefrontal cortex
     5-HIAA 510 ± 22.4 618 ± 33.5* 473 ± 30.2
Hippocampus
     5-HT 110 ± 6.5 83 ± 8.5 115 ± 8.2#
Hypotalamus
     5-HT 385 ±25.7 329 ± 21.2 453 ± 27.9##
DOPAC/DA 1.21 ± 0.15 1.65 ± 0.43# 1.17 ± 0.09
* P < 0.05, ** P < 0.01 significant changes from the control group. 
# P < 0.05, ## P < 0.01 significant changes from the other nandrolone group.
Data is expressed as mean ng amine/g tissue ± s.e.m. n = 10–12. 
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5.1.2  Blood parameters
Figure 10 summarizes the effects of nandrolone (5 and 20 mg/kg) on the blood 
count. The effects of nandrolone on erythrocyte, hemoglobin and reticulocyte 
concentrations were statistically significant. In addition, after nandrolone 
treatment the levels of hemoglobin and erythrocytes increased, and reticulocyte 
levels decreased. The change in concentrations of hemoglobin, erythrocytes and 
reticulocytes, when compared with the control group, was significant only after 
the lower dose. The dose of 20 mg/kg nandrolone reduced plasma creatinine 
concentrations. 
Figure 10. Comparison of the two different doses of nandrolone decanoate and arachinoid 
oil (control) on different blood parameters. Samples were collected after decapitation. Data 
expressed as percentages of basal level (control group = 100 %), and are given as means ± 
SEM. *P < 0.05, compared to control group, Bonferroni’s test (N = 6). Only the results which 
have been found statistically significant (p < 0.05) in the original papers are presented here.
Cont = Control/vehicle, D5 = nandrolone decanoate 5 mg/kg, D20 = nandrolone decanoate 20 
mg/kg. 
5.2  The combined effects of nandrolone and  
 stimulant drugs
The pre-treatment with nandrolone did not affect spontaneous release of the 
transmitters or their metabolites. The basal levels also remained unaltered after 
acute saline injection during the microdialysis experiments (see for original 
publications). 
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The increase in extracellular DA concentration induced by amphetamine, 
MDMA and cocaine in the NAc was attenuated by sub-chronic treatment with the 
AAS, nandrolone. The magnitude of changes depended on the dose of nandrolone 
administered. Both doses of nandrolone also inhibited cocaine induced 5-HT 
outflow in the NAc dose-dependently. However, only the lower dose of nandrolone 
attenuated MDMA-induced increase in 5-HT-levels, while the higher dose 
potentiated it. 
Table 5 summarizes the effects of nandrolone co-treatment with amphetamine, 
MDMA and cocaine on extracellular concentrations of DA, 5-HT and their 
metabolites in the NAc.
TABLE 5. Summary of the acute effects of psychostimulant drugs alone and co-treated with 
nandrolone decanoate on the extracellular concentrations of DA, 5-HT and their metabolites 
in the NAc.
Treatment DA DOPAC HVA 5-HT 5-HIAA
Amphetamine
Nandro 5 + Amphetamine
Nandro 20 + Amphetamine
↑↑↑↑↑
↑↑↑↑
↑↑↑
↓↓
↓
↓
↓
↓
↓
-
-
-
-
-
-
MDMA
Nandro 5 + MDMA
Nandro 20 + MDMA
↑↑↑↑
↑↑↑
↑↑
↓↓
↓
↓
↓↓
↓
↓
↑↑↑↑↑
↑↑↑↑
↑↑↑↑↑↑
↓
↓
↓↓
Cocaine
Nandro 5 + Cocaine
Nandro 20 + Cocaine
↑↑↑↑
↑↑↑
↑↑
↓
↓
↓
↓
↓
↓
↑↑↑
↑↑
↑
-
-
-
The arrows show the change induced by drug treatments: ↑ maximal increase to more than 100 % 
of the basal output, ↑↑ max increase to more than 200 %, ↑↑↑ max increase to more than 300 %, 
↑↑↑↑ max increase to more than 600 %, ↑↑↑↑↑ max increase to more than 1000 %, ↑↑↑↑↑↑ 
max increase to more than 2000 %, ↓ max decrease to less than 80 %, ↓↓ max decrease to less 
than 50 %. All results presented here with arrows have been found statistically significant (p < 
0.05) as evaluated by statistical tests in the original papers; (-) indicates no significant change. 
5.2.1 Behavior
Amphetamine, MDMA and cocaine produced a rapid and long lasting increase in 
locomotor activity and stereotypic behavior (Figure 11). Nandrolone pre-treatment 
per se or acute saline injections did not alter the behavior of the rats. Analysis of 
the behavioral data suggests that effects of amphetamine, MDMA and cocaine are 
attenuated by AAS-treatment, paralleling observed monoamine results. After the 
stimulant injection, the behavior of the nandrolone-pretreated animals was less 
stereotyped than those observed animals pre-treated with vehicle-oil. Nandrolone 
pre-exposure also modified the ability of amphetamine, MDMA and cocaine to 
cause increased locomotor activity. Both nandrolone doses decreased stimulant 
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drugs induced locomotor activity, although the difference to when compared to 
vehicle treated animals was statistically significant only with the higher nandrolone 
dose with amphetamine and MDMA. The lack of statistical significance seems to 
be due to a higher variation among 5 mg/kg group.
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FIGURE 11. The behavioral effects of amphetamine, MDMA and cocaine together with 
nandrolone pre-treatment at doses of 5 and 20 mg/kg. Stimulant drugs were administered 
at 0 min. Data are given as means ± SEM (n = 6). 
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5.2.2  Blood drug concentrations
According to our preliminary study of one brain sample per treatment group, 
subchronic i.m. pre-treatment with nandrolone at doses of 5 and 20 mg/kg caused 
only negligible changes in brain tissue amphetamine concentration: results for all 
treatment groups were between 3.0 and 4.0 µg/g, with the lowest concentration 
measured for the group that received no nandrolone. In the case of MDMA  (n = 
2), however, the preliminary study showed more variable results: the MDMA brain 
concentrations in animals treated with arachinoid oil, nandrolone 5 mg/kg, and 
nandrolone 20 mg/kg were 5.2, 1.7, and 2.0 µg/g respectively. Therefore, MDMA 
was also measured from blood samples from 19 animals that were included 
in the neurochemical and behavioral study. The means of the MDMA blood 
concentrations in all treatment groups were 0.10–0.11 µg/ml. The concentrations 
of cocaine, benzoylecgonine or ecgonine methyl ester did not statistically differ 
between treatment groups. 
5.2.3  Neurochemical and behavioral correlation
Correlation analysis between neurochemical and behavioral data was carried out. 
DA, its metabolites and 5-HT concentrations correlate strongly with locomotor 
activity and stereotyped behaviour after stimulant dosing (Table 6).
TABLE 6. Correlation between neurochemical and behavioral data.
Correlation between DA DOPAC HVA 5-HT 5-HIAA
All animals:
Behavior
Locomotor activity  
.890***
.721***
-.636**
-.521**
.468**
.414**
.871**
.701**
-.261
-.273
**p ≤ 0.05 ***p ≤ 0.001. Data shown as correlation coefficient.
5.3  The effect of recovery period 
5.3.1  Blood concentrations
Blood concentrations of nandrolone are show in figure 12. Animals treated with 
nandrolone decanoate differed from vehicle treated animals, as expected. The only 
exception was the 5 mg/kg -group after 28 recovery days, which did not differ 
statistically from the control groups. Every group after 28 recovery days differed 
statistically from the corresponding group after 6 recovery days in nandrolone 
concentration.
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FIGURE 12. The effects of sub-chronic nandrolone i.m. injections on blood concentration of 
nandrolone (μg/l) in time of decapitation. 
The values are expressed as mean ± SEM, ***p ≤ 0.001
Cont/28 = Control 28 day recovery period, Cont/6 = Control 6 day recovery period, D5/28 = 
nandrolone 5 mg/kg 28 day recovery period, D5/6 = nandrolone 5 mg/kg 6 day recovery period, 
D20/28 = nandrolone 20 mg/kg 28 day recovery period, D20/6 = nandrolone 20 mg/kg 6 day 
recovery period.
5.3.2  Monoamines
The temporal profiles of the effects of nandrolone pre-treatments and cocaine 
injections on extracellular DA and 5-HT levels after 6- and 28-day recovery periods 
are shown in figure 13. Nandrolone pre-treatment decreased dose-dependently the 
cocaine-induced elevation of extracellular DA- and 5-HT-levels as compared to the 
vehicle. The length of the recovery period (6 fc. 28 days) had no effect on cocaine’s 
action per se. The attenuating effect of nandrolone pre-treatment on cocaine-
induced elevation of extracellular DA and 5-HT remained persistent over the 28-
day recovery period after the last nandrolone dose. The absolute basal accumbal 
extracellular concentrations of DA and 5-HT did not differ significantly between 
the treatment groups. The levels remained unaltered in groups injected with saline 
after basal samples. 
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FIGURE 13. The effect of acute cocaine (20 mg/kg) on extracellular DA and 5-HT levels in the 
NAc after 6 days or 28 days from the last nandrolone dose. Cocaine was administered at 0 
min. Data expressed as percentages of basal release are given as means ± S.E.M. (n = 6). 
All results presented here have been found statistically significant (p < 0.05) as evaluated 
by statistical tests in the original papers.
5.3.3  Behavior
Nandrolone pre-exposure modified the ability of cocaine to increase locomotor 
activity and stereotyped behavior. The effect of nandrolone dosing on cocaine-
induced behavioral changes remained persistent over the 28-day recovery period 
when compared to the 6-day recovery period as seen in figure 14. The only exception 
was the nandrolone 5 mg/kg 28-day recovery -group in which the dose failed to 
attenuate statistically the locomotor activity induced by cocaine. The length of the 
recovery period (6 vs. 28 days) had no effect on cocaine’s action per se.
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FIGURE 14. The effect of acute cocaine (20 mg/kg) injection on stereotyped behavior and 
locomotor activity after 6 days or after 28 days from the last nandrolone injection. Cocaine 
was administered at 0 min. (n = 6). 
5.4 The effects of androgen and estrogen   
 receptor blockade on nandrolone’s    
 attenuating effect on psychostimulant-  
 induced neurochemical changes 
The pretreatment with nandrolone (20 mg/kg) decreased the amphetamine-
induced elevation of extracellular DA levels and increased the DOPAC and HVA 
levels compared to vehicle-oil treatment in the NAc. 
Administration (i.g), of androgen and estrogen receptor antagonists, prevented 
nandrolone’s attenuating effect on amphetamine-evoked monoamine release in the 
NAc as seen in figure 15. The dose of 50 mg/kg of flutamide, administered before 
nandrolone injection, restored the DA releasing effect of amphetamine. Flutamide 
compensated the modifying effects of nandrolone after amphetamine injection 
 
-20 0 20 40 60 80 100 120 140 160
1
2
3
4
5
6
7
-20 0 20 40 60 80 100 120 140 160
0
5
10
15
20
25
30
35
40
-20 0 20 40 60 80 100 120 140 160
1
2
3
4
5
6
7
-20 0 20 40 60 80 100 120 140 160
0
5
10
15
20
25
30
35
40
TIME (m in)
TIME (m in)TIME (m in)
Day 6  Vehicle/Saline
 Vehicle/Cocaine
 Nandr 5m g/kg/Cocaine
 Nandr 20m g/kg/Cocaine
Day 28Day 6
Locom otor activ ity (passes across m idline)
Behavioral Score
Day 28
TIME (m in)
 Vehicle/Saline
 Vehicle/Cocaine
 Nandr 5m g/kg/Cocaine
 Nandr 20m g/kg/Cocaine
5   Results
50 Interactions of Nandrolone and Psychostimulant Drugs 
on Central Monoaminergic Systems
Research 30/2010
National Institute for Health and Welfare
also on extracellular DOPAC and HVA levels. The dose of 20 mg/kg of clomiphene 
(i.g.), administered before nandrolone injection, restored in part the DA releasing 
effect of amphetamine and also compensated the modifying effects on extracellular 
HVA levels. Pre-treatment with clomiphene seemed to have the same kind of effect 
on DOPAC, but without the statistical significance. Pre-treatment with nandrolone 
and flutamide or clomiphene did not affect spontaneous release of the transmitters 
or their metabolites. 
FIGURE 15. The effects of pre-treatment of flutamide (50 mg/kg) or clomiphene (20 mg/
kg), and nandrolone (20mg/kg) together with acute amphetamine (1 mg/kg) injections (at 
0 min) on extracellular DA and 5-HT levels in the NAc. Data expressed as percentages 
of basal release are given as means± S.E.M. (n = 5-6). All results presented here have 
been found statistically significant (p < 0.05) as evaluated by statistical tests in the original 
papers.
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6	 Discussion
6.1  The effects of nandrolone in brain regions  
 regulating motivation and reward-related  
 associative learning
In this study (paper I), increased levels of DOPAC as well as 5-HT were seen in 
the cerebral cortex after nandrolone dosing. Also, the lower dose of nandrolone 
significantly increased the DOPAC/DA ratio in the hypothalamus and 5-HIAA 
levels in the prefrontal cortex. DOPAC/DA ratio increased quite also in prefrontal 
cortex, however without statistical significance. Even though the few results of AASs 
effects on brain monoamine systems seen are diverse, our findings in the cerebral 
cortex are in line with previous studies indicating dopaminergic and serotonergic 
dysregulation in the rat brain following administration of nandrolone decanoate.
The drawback of the studies made is that findings on AAS induced changes in 
monoaminergic systems are not explicit. Aggregated data suggests that testosterone 
ultimately alters DA activity in the NAc (Thiblin et al., 1999) and chronic exposure 
to nandrolone affects the levels of DA receptors (Kindlundh et al., 2001b; Kindlundh 
et al., 2003b) and increase of DAT protein observed by binding studies done with 
in vitro autoradiography and PET technology (Kindlundh et al., 2002; Kindlundh 
et al., 2004) in rat brain. It has also been difficult to establish a uniform pattern of 
AASs’ effects on rat brain 5-HT, possibly due to differences in study designs. There 
are results where AASs have no effect on 5-HT concentration in rat brain (Vermes 
et al., 1979), results where AAS treatment lowered the level of 5-HT (Lindqvist 
et al., 2002) and contrary results where Tamaki et al. (2003) recently observed 
increased levels of 5-HT and 5-HIAA in the cerebral cortex and hypothalamus 
after nandrolone treatment (more details are given in the section Review of the 
Literature). These inconsistent findings demonstrate that nandrolone does not 
have a uniform effect in all brain regions, all cell types in the same region, nor at all 
receptor types on the same neuron. 
When speculating on the possible mechanisms that mediate nandrolone’s 
action on monoamine metabolism, the possible activation of MAO is excluded, 
since it would have increased the metabolism of both 5-HT and DA, but in this 
experiment only DA metabolism was increased. This is in concert with an earlier 
study where nandrolone propionate had no effect on MAO-A activity (Thiblin et 
al., 1999). Our results here are limited by difficulty in determining whether the 
changes in 5-HT concentration correspond to an increased secretion or synthesis, 
or both, of 5-HT. However, on the basis of the sub-chronic nature of the treatment, 
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we believe that the altered levels observed in this study correspond principally to 
an increased biosynthesis, because an increased release is more likely to be an acute 
effect. There is a need for future studies to investigate the impact of varied AAS 
treatments on the mediating brain reward system.
It is tempting to speculate whether chronic treatment with supra-therapeutical 
doses of nandrolone mainly reflects a stimulatory influence on the mesolimbic DA 
system rather than the nigro-striatal DA system. Stimulation of the mesolimbic 
DA system is known to be related to reward (Koob, 1992). Taken together, these 
data indicate that an increase in dopaminergic neuronal activity might account for 
some of the positive effects, e.g. euphoria and increased self-esteem and confidence, 
which frequently appear as early effects following the administration of AASs to 
humans (Corrigan, 1996; Su et al., 1993). 
Sub-chronic administration of nandrolone increased erythrocytes and 
hemoglobin concentrations, but reduced the growth of body mass and reduced 
levels of creatinine. The results are in line with earlier reports showing that use 
of AASs induces the synthesis of erythrocytes (Wu, 1997), increases hemoglobin 
concentrations (Besa, 1994; Shahidi, 1973) and decreases weight gain (Johansson 
et al., 2000a; Johansson et al., 2000b; Lindqvist et al., 2002). Decreased weight 
gain may be a consequence of reduced food intake, reported after nandrolone 
administration (Lindblom et al., 2003; Yu-Yahiro et al., 1989), but food consumption 
was not recorded in our study. 
However, the concentrations of reticulocytes were unexpectedly reduced. This 
inverse effect may be explained by the rapid increase in red-cell mass. Although 
the administration of AASs to humans and laboratory animals has been associated 
with increased erythropoietin activity and an increased pool of erythropoietin 
responsive stem cells, this mechanism has not yet been entirely clarified. 
Somewhat surprisingly, the effects of the lower dose appeared to be more 
pronounced than the effects of the higher dose, although the effects of AASs are 
generally considered to be dose related (Shahidi, 2001). Given that nandrolone has 
been shown to have a higher androgen receptor binding affinity than testosterone 
(Kumar et al., 1999; Roselli, 1998), and dosing in this study was highly supra-
therapeutical, it can be speculated whether that saturation of androgenic receptors 
occurs already at the lower nandrolone dose. The apparently more pronounced 
effects of the lower dose could reflect the situation where this nandrolone dose 
has anabolic effects, while the extreme dose may cause spill over on other steroid 
receptors, e.g. the corticoid receptors, thereby triggering catabolic processes 
counteracting the androgen receptor mediated effects. Such a mechanism 
(catabolism) is in line with the significant loss of growth and reduced levels of 
creatinine displayed by the higher nandrolone treated animals.
Taken together, it appears that nandrolone at doses, high enough to induce 
erythropoiesis, induces changes in the dopaminergic and serotonergic neuronal 
systems in the brains of rats. These phenomena may account for some of the 
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observed central stimulatory properties that have been reported following AAS 
abuse. 
6.2  The combined effects of nandrolone and  
 stimulant drugs
The main findings of the present series of experiments are that sub-chronic pre-
treatment with nandrolone decanoate attenuates dose-dependently the reward-
related neurochemical and behavioral effects of acute amphetamine, MDMA 
and cocaine administration. Our findings are in line with the reported ability 
of nandrolone to decrease morphine-reward (Celerier et al., 2003) as well as 
preliminary findings (Mcallister and Compton, 1995) indicating that chronic 
administration of AASs blunts the subjective effects of cocaine in rats. The increase 
in extracellular DA concentration induced by amphetamine, MDMA and cocaine 
in the NAc was attenuated by sub-chronic treatment with the two different 
nandrolone doses, and both nandrolone doses also evoked changes in extracellular 
levels of 5-HT after MDMA and cocaine dosing.
The whole cascade of monoamine action, from synthesis to receptor 
activation, provides several possible mechanisms by which nandrolone might 
affect the dopaminergic and serotonergic response to stimulants. To exclude 
the additional possibility that drug pharmacokinetics are a mechanism, which 
would lead to a misinterpretation of data, we measured the blood MDMA and 
cocaine concentrations, proving that the ability of nandrolone to modulate the 
neurochemical and behavioral effects of stimulants is not due to nandrolone-
induced changes in pharmacokinetics. As stated in the Review of the literature 
(Sections 2.2.1.2 and 2.2.2.2), there are only a few reports of the ability of nandrolone 
to affect DA or 5-HT synthesis or metabolism, and these reports are fairly diverging. 
Nevertheless, in the studies done here, nandrolone failed to affect the basal levels 
of DA, 5-HT and their metabolites in extracellular space in the NAc. Thus it seems 
that the steps of DA and 5-HT transmission (synthesis, storage or release), in all 
likelihood, are not the primary target of nandrolone action, but are, rather, in some 
other mechanisms mediated by transporter proteins or postsynaptic receptors. 
Mechanisms of action of the amphetamines include both DA and 5-HT reverse-
transport and uptake inhibition and have markedly complicated the assessment of 
nandrolone actions on DAT and SERT. However, the dosing of cocaine, which can 
be considered as a pure uptake inhibitor, supports the hypothesis that nandrolone 
modifies the dopaminergic response to the psychomotor stimulant drug via DAT. 
This is supported by studies where chronic nandrolone treatment has been reported 
to increase both the amount of DAT and its affinity to DA (Kindlundh et al., 2002; 
Kindlundh et al., 2004). It seems plausible that – analogously with dopaminergic 
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effects – the possible increase in SERT density might lead to increased reuptake 
capacity and hence to decreased 5-HT concentration in the extracellular space 
after MDMA and cocaine administration. Testosterone has been shown to increase 
the expression of SERT mRNA and the density of SERT sites in the forebrain 
(McQueen et al., 1999), but to the author’s knowledge, no studies have been 
carried out with nandrolone. Our interpretation of the data – that upregulation 
of DAT and SERT sites would lead to reduction in cocaine effects – is based on an 
assumption that the 20 mg/kg dose of cocaine used in this study, does not saturate 
the DAT binding sites. There are, indeed, several studies that show that 40 mg/
kg dose increases the extracellular concentration of DA and 5-HT in rat brain as 
compared to 20 mg/kg dose (Chen and Reith, 1994; Martin-Fardon et al., 1996; 
Sorge et al., 2005; Szumlinski et al., 2000). If the pre-treatment with nandrolone 
adds up the number of DAT and SERT, as speculated here, you can think that more 
DA and 5-HT is transported into the cell, because there are now more intact DAT 
and SERT. 
However, the effects of nandrolone on MDMA-induced elevation of 5-HT 
levels were two sided: the lower dose of nandrolone decreased the effect of 
MDMA, while the higher dose potentiated it. Damage to 5-HT terminals following 
high doses of MDMA is well documented (O’Hearn et al., 1988; Ricaurte et al., 
1993) and it is preceded by an acute stage in which substantial release of 5-HT 
leads to exhaustion of the neuronal 5-HT stores. An apparently similar outflow 
of 5-HT was observed after MDMA injection in rats pre-treated with the higher 
dose of nandrolone. Therefore, it can be speculated that high-dose sub-chronic 
nandrolone treatment might increase cell vulnerability to MDMA, leading to effects 
resembling the acute toxicity at lower concentrations of MDMA. This is supported 
also by behavioral results were animals locomotor activity were almost completely 
paralyzed. There is strong possibility that this is a reflection of the so-called 5-HT 
syndrome in rat (Grahame-Smith, 1971). Whether this phenomenon results from 
increased vulnerability of the neurons to acute stage of MDMA neurotoxicity or to 
some other mechanism, remains to be elucidated. 
Acute administration of amphetamine, MDMA and cocaine, all induced a 
rapid and long-lasting increase in locomotor activation and stereotypic behavior. 
Furthermore, nandrolone pre-treatment attenuated dose-dependently both 
locomotor activity and stereotyped behavior induced by these stimulant drugs. 
These results are concordant with earlier studies in which testosterone has been 
shown to attenuate amphetamine induced locomotor activity and stereotyped 
behavior (Beatty et al., 1982; Dluzen et al., 1986; Savageau and Beatty, 1981). 
Correlation with microdialysis results is to be expected, because stimulant-induced 
hyperlocomotion is predominantly mediated by increased release of DA in the 
NAc (Bedford et al., 1980; Creese and Iversen, 1974; Wellman et al., 2002). One 
exception was that even though there was a potent increase in 5-HT concentration 
after the higher nandrolone dose and MDMA, there was no remarkable increase in 
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behavioral scores. This could be a result of significantly lowered DA concentration. 
Indeed, more lateral and vertical repetitive head movements, vigorous sniffing, 
forepaw treading and head weaving, many of which resemble behaviors 
characteristic of the so-called 5-HT syndrome in rat (Grahame-Smith, 1971), were 
seen in this group. 
In conclusion, these data show that treatment with supra-therapeutical doses 
of the AAS, nandrolone decanoate, attenuates reward-related neurochemical 
effects as well as behavioral effects, induced by amphetamine, MDMA and cocaine 
dosing. 
Correlation analysis between neurochemical and behavioral data was carried 
out and DA, its metabolites and 5-HT concentrations correlate strongly with 
locomotor activity and stereotyped behaviour seen after stimulant dosing, which 
is to be expected since it well established that monoamine concentrations in the 
NAc are strongly related to activation of locomotor and stereotyped behavior (see 
Review of the literature 2.3). 
6.3  The effect of recovery period 
The main finding of the present experiment (paper III) is that nandrolone-induced 
attenuation of reward-related neurochemical and behavioral effects caused by 
acute cocaine administration is seen for at least 28 days after the last nandrolone 
injection, despite the significant decrease in blood nandrolone concentration. The 
length of the recovery period (6 vs. 28 days) had no effect on cocaine’s action per 
se. The extracellular concentrations of DA, and its metabolites, in samples collected 
from the NAc after the cocaine injection did not differ statistically between 
the 6-day recovery period group and the 28-day recovery period group. The 
attenuating effect of nandrolone on cocaine-induced elevation of extracellular DA 
also remained persistent over the 28-day recovery period. In addition, the effect of 
nandrolone on cocaine-induced behavioral changes remained persistent over the 
28-day recovery period. The only exception was the lower nandrolone dose 28-
day recovery group, which failed to attenuate statistically the locomotor activity 
induced by cocaine. These results are in line with the concept that addictive drugs 
are hypothesized to produce changes in brain dopaminergic pathways that endure 
long after the person stops taking the drugs. There are several studies showing 
that chronic administration of cocaine and methamphetamine is associated with, 
among other things, a decrease in D2 receptors and DAT during withdrawal, and 
changes, when compared to non-users, can last up to 11 months after the last drug 
dosing (Volkow et al., 2001a; Volkow et al., 2001b; Volkow et al., 1990). 
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6.4  The effects of androgen and estrogen   
 receptor blockade on nandrolone’s    
 attenuating effect on psychostimulant-  
 induced neurochemical changes 
The main finding of this series of experiments is that pre-treatment with the 
androgen receptor antagonist flutamide robustly prevents, and the estrogen 
receptor antagonist clomiphene partly reduces, the nandrolone’s attenuating effect 
on increased extracellular DA in the NAc after amphetamine dosing.
The literature concerning the role of androgen and estrogen receptors in drug 
reward is scarce. In the study of Frye, flutamide failed to attenuate conditioned 
place preference (CPP) induced by a testosterone secondary metabolite, 3α-diol 
(Frye, 2007). These results, however, do not necessarily conflict with our findings, 
even though both methods may give an estimate of addictive potential of a drug. In 
the experimental set-up used by Frye (2007), the receptor blocker flutamide itself 
was found to cause CPP, which makes the results extremely difficult to interpret.
Intracellular ARs (the so-called “classical” receptors), are found in the NAc, 
but their density is shown to be relatively low (Balthazart et al., 1998; Stumpf and 
Sar, 1976). Therefore, it is possible that the site of action could be outside the NAc, 
although the number of receptors in the brains of the animals may be higher due to 
the sub-chronic treatment with nandrolone, which has been shown to up-regulate 
intracellular (nuclear) AR in male rats (Menard and Harlan, 1993; Wesson and 
McGinnis, 2006). Outside the NAc, steroids may regulate monoamine release 
indirectly by modulating the activity of ascending inputs from monoaminergic 
nuclei that project to the NAc: the circuits via which nuclear AR-positive cells in 
bed nucleus of the stria terminalis and medial preoptic area projecting to the ventral 
tegmental area (VTA). Androgen sensitive cells in the lateral hypothalamus project 
to the VTA as well (Sato et al., 2008), and VTA itself contains some androgen 
receptors (Kritzer, 1997). These projections provide an opportunity for androgens 
to modify the activity of the mesocorticolimbic DA system. Finally, many of the 
brain areas that supply afferents to midbrain DA nuclei are themselves rich in 
classical steroid receptors, and are in a position to provide powerful, albeit indirect, 
genomic influence over the midbrain system (Kritzer, 1997). Recent studies in rats 
have also demonstrated rapid cellular effects of androgens in brain regions that 
possess only relatively few classical receptors (Mermelstein et al., 1996). These 
faster androgen actions are thought to be mediated by “non-classical” receptors, 
the membrane steroid receptors (Sato et al., 2008). Whereas the distribution of 
classical steroid receptors in rodent brain is relatively limited, the potential brain 
targets for androgen action via membrane receptors are much broader.
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Aromatase transforms some portion of the androgens to estrogens through 
oxidation and subsequent elimination of a methyl group (Schade and Schubert, 
1979). Nandrolone is shown to be a substrate for aromatase enzyme (Ryan, 1959) 
and is shown to stimulate the aromatase activity, which is related to the ability 
of estrogens of nandrolone origin to bind estrogen receptors in rat brain (Roselli, 
1998). This is in line with findings of ours, that blockade of ER also reduces 
partly the nandrolone’s ability to attenuate amphetamine-induced increase in 
extracellular DA in the NAc. It is suggested that the modifications of both ARs and 
ERs in the NAc by AASs, and likely AAS metabolites, are responsible for behavioral 
complexity associated with abuse of anabolic steroids (van de Poll et al., 1986).
Steroid receptors, when occupied by a ligand, act as transcription factors 
to modulate gene expression, which in turn results in a host of neurobiological 
changes. Receptor activation could lead to alterations in neuronal excitability 
and signal transduction in brain regions implicated in addiction, which in turn 
could change the organism’s neurochemical response to stimulant drugs in brain. 
However, because this study gives little further indication on the mechanism by 
which these effects are mediated, they are not further discussed here. 
Even with evidence as strong as seen here of involvement of the ARs and ERs, it 
has to be remembered that synthetic AASs and their metabolites do not only bind to 
ARs and ERs but also, with higher doses, to glucocorticoid and progestin receptors 
(Janne, 1990). They have also been shown to interact with GABA (Masonis and 
McCarthy, 1995) and 5-HT receptors (Kindlundh et al., 2003a). Consequently, the 
effects of AAS are far from purely androgenic and may involve actions at multiple 
genomic and non-genomic substrates. These other mechanism could explain some 
the minor peripheral effects seen here, however, if receptor blocking is presumed 
to be fairly selective, there can be said that the brain effects seems to mediated via 
ARs and ERs.
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7	 Summary	and	conclusions
This thesis reports alterations in the male rat brain dopaminergic and serotonergic 
systems, induced by subchronic nandrolone decanoate administration and 
co-administration with psychostimulant drugs. The reduced activation of 
dopaminergic neurons may correspond to the increased prevalence of illicit 
drug usage among people who self-administer AASs and abusers of AASs may 
require larger doses of drugs to achieve the desired effects. However, because pre-
treatment with nandrolone substantially decreases the efficacy of stimulant drugs 
on extracellular DA and 5-HT as well as related behaviors in the present studies, 
it could be speculated that compounds acting like steroids at central receptors or 
transporter proteins may provide a useful approach in the research of stimulant 
abuse treatment. These findings provide insight into the physiological role of 
steroids and the biology of stimulant dependence. 
The main outcomes from the studies included in this thesis are:
1)  Nandrolone decanoate at doses, high enough to induce erythropoiesis, 
induces changes in the dopaminergic and serotonergic system in the in the 
cerebral cortex, the area that regulates motivation and emotions as well as 
higher cognitive functions.
2)  Amphetamine, MDMA and cocaine induced hedonic effects, as measured 
by increasing of extracellular DA and 5-HT in NAc and increased locomotor 
activity, as well as stereotyped behavior are attenuated dose-dependently by 
sub-chronic treatment with nandrolone. The results suggest that chronic AAS 
treatment alters neurochemical and behavioural responses related to stimulant 
addictive properties.
3)  Despite the significant decrease in nandrolone concentration in blood, the 
attenuation of cocaine’s effects remained unchanged after a fairly long period 
without nandrolone (28 days cf. 6 days), suggesting that AAS treatment would 
produce long-term changes in reward brain circuits. 
4) Androgen receptor antagonism attenuated the effects of nandrolone 
pretreatment on amphetamine-induced elevation of extracellular DA and 
5-HT concentrations in NAc suggesting that hormonal systems are involved 
in AASs ability to modulate the dopaminergic and serotonergic effects of 
acute injection of amphetamine. So, it seems that the ability of nandrolone to 
modulate reward-related effects of amphetamine is, at least in part dependent 
on activation of the ARs or ERs. 
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